Source,Regular_Expression,Match,Manual_Verification,SMILES,Drug_Name,Class
https://doi.org/10.1038/s41598-019-39490-x,.*does not cross the blood.brain barrier.*," To test this hypothesis, mice were systemically pre-treated with a mAChR antagonist that does not cross the blood-brain barrier, (−)-scopolamine methyl bromide (i",Pass,-,(−)-scopolamine methyl bromide,0
https://doi.org/10.1186/s13023-021-02063-1,.*does not cross the blood.brain barrier.*," Since ERT has no effects on neurological signs (it does not cross the blood–brain barrier), hematopoietic stem cell transplantation (HSCT) with bone marrow or umbilical cord blood stem cells has been performed, as in other lysosomal diseases, showing diverse outcomes",Fail,-,,
https://doi.org/10.1007/s12031-019-01307-x,.*does not cross the blood.brain barrier.*," The final, inactive, olanzapine metabolite 10-N-glucuronide does not cross the blood-brain barrier (Aravagiri et al",Pass,-,10-N-glucuronide,0
https://doi.org/10.1186/1756-0500-6-277,.*does not cross the blood.brain barrier.*,Data obtained from tissue-autoradiography of rats infused with 14C-3-BrPA showed strong 14C-signal in tissue sections of various organs except the brain corroborating that 3-BrPA does not cross the blood–brain barrier,Pass,C(C(=O)C(=O)O)Br,3-BrPA,0
https://doi.org/10.1038/s41598-017-18747-3,.*inability to cross the blood.brain barrier.*," The lack of effect of 2-F-4-AP can be explained by the lack of binding to the channel, as demonstrated in the previous experiments, whereas the lack of effect of 3-HOMe-4-AP is likely due to its inability to cross the blood-brain barrier (BBB) as predicted by its cLogP of −0",Pass,-,3-HOMe-4-AP,0
https://doi.org/10.1007/s00018-021-03944-1,.*does not cross the blood.brain barrier.*," High binding in pancreas, liver, adipose, kidney, adrenal glands and heart was observed, with negligible binding in the brain, indicating that the peptide does not cross the blood–brain barrier when peripherally injected",Fail,-,,
https://doi.org/10.1038/sj.cgt.7700978,.*inability to cross the blood.brain barrier.*,"Systemic 5-FU is the mainstay of chemotherapy of several malignancies (colon, pancreatic and other GI carcinomas);35, 36 however, its inability to cross the blood–brain barrier, systemic toxicities and other pharmacokinetic factors have mitigated against its use for routine therapy of gliomas,37, 38 reviewed by Mahaley",Pass,C1=C(C(=O)NC(=O)N1)F,5-FU,0
https://doi.org/10.1007/s10072-021-05615-2,.*unable to cross the blood.brain barrier.*,The CNS outcomes’ sub-investigation in FD was probably due to a shared concept that enzyme replacement therapy (ERT) is not useful because it is unable to cross the blood–brain barrier,Fail,-,,
https://doi.org/10.1038/leu.2011.62,.*does not cross the blood.brain barrier.*," However, 6OHDA treatment of adult mice, which does not cross the blood–brain barrier, did not affect AMD3100-induced mobilization (Figure 5e), suggesting that this effect is mediated by the central nervous system",Pass,-,6OHDA,0
https://doi.org/10.1007/s12640-017-9824-8,.*does not cross the blood.brain barrier.*," Because 6-OHDA does not cross the blood-brain barrier, obtaining a toxic effect in the central nervous system is possible after a direct injection of this compound into the corresponding brain structures by means of stereotaxic surgery",Pass,C1=C(C(=CC(=C1O)O)O)CCN,6-OHDA,0
https://doi.org/10.1007/s40261-021-01071-0,.*inability to cross the blood.brain barrier.*,"t) administered, due to its inability to cross the blood-brain barrier (BBB)",Fail,-,,
https://doi.org/10.1038/s41598-019-39591-7,.*does not cross the blood.brain barrier.*," Additionally, 8-azaguanine does not cross the blood-brain barrier nor is it intercalated or incorporated into DNA",Pass,C12=NNN=C1N=C(NC2=O)N,8-azaguanine,0
https://doi.org/10.1186/2051-5960-2-62,.*does not penetrate the blood.brain barrier.*," Since A-317491 does not penetrate the blood–brain barrier [14], its anti-nociceptive effect is restricted to the periphery",Pass,C1C[C@@H](C2=CC=CC=C2C1)N(CC3=CC(=CC=C3)OC4=CC=CC=C4)C(=O)C5=CC(=C(C=C5C(=O)O)C(=O)O)C(=O)O,A-317491,0
https://doi.org/10.1186/s12933-018-0800-2,.*does not cross the blood.brain barrier.*," Albiglutide is a large biochemical entity that does not cross the blood–brain barrier, which may possibly underlie the fewer nausea events experience with albiglutide than with other GLP-1RAs [59]",Pass,CC[C@@H](C)[C@@H](C(=O)N[C@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N,Albiglutide,0
https://doi.org/10.1186/1742-2094-9-24,.*does not penetrate the blood.brain barrier.*," Because α-BGT does not penetrate the blood-brain barrier, the drug was administered intracerebroventricularly at a dose of 0",Pass,-,alpha-BGT,0
https://doi.org/10.1038/s41436-021-01156-3,.*does not cross the blood.brain barrier.*,"11 Enzyme replacement therapy (ERT) with olipudase alfa (recombinant human ASM, which does not cross the blood–brain barrier) is in clinical development to treat non–central nervous system manifestations of ASMD",Fail,-,,
https://doi.org/10.1038/s41467-021-24567-x,.*does not cross the blood.brain barrier.*," b RapaBlock (pink), a small molecule that does not cross the blood–brain barrier (BBB) (green) and competes with RapaLink-1 (purple) for FKBP12 (yellow) binding in the periphery, protects mTORC1 activity outside of the CNS",Fail,-,,
https://doi.org/10.1038/sj.npp.1300393,.*does not cross the blood.brain barrier.*," Similarly, investigation of the α7 nAChR subtype using the selective antagonists α-bungarotoxin and methyllycaconitine has proven difficult as the former is a large peptide which does not cross the blood–brain barrier, while there is now some debate over the selectivity of the latter (Mogg et al, 2002)",Pass,C[C@@H]1C[C@H]2[C@@H](C[C@]3([C@H](O2)C[C@H]4[C@H](O3)C(=CC(=O)O4)C)C)O[C@@H]5[C@@H]1O[C@H]6C[C@@H]7[C@](C[C@@H]8[C@@](O7)(C/C=C\[C@@H]9[C@@H](O8)C[C@@H]1[C@@H](O9)C[C@@H]2[C@@](O1)([C@H](C[C@@H](O2)CC(=C)C=O)O)C)C)(O[C@@]6(CC5)C)C,alpha-bungarotoxin,0
https://doi.org/10.1038/s41380-021-01221-y,.*unable to cross the blood.brain barrier.*," Second- and third-generation CB1 antagonists unable to cross the blood–brain barrier might have been used instead [3], as also recently suggested by Cinar et al",Fail,-,,
https://doi.org/10.1016/S0893-133X(98)00032-3,.*does not cross the blood.brain barrier.*," Because αM5HT is not a substrate for monoamine oxidase and does not cross the blood–brain barrier, it accumulates in the brain",Pass,-,alphaM5HT,0
https://doi.org/10.1186/s43094-021-00289-1,.*unable to cross the blood.brain barrier.*,The root cause of limited success in treatments of neurological disorders is the route of administration as many drug molecules failed to show their influence because they are unable to cross the blood–brain barrier (BBB) when administered by oral or parenteral route,Fail,-,,
https://doi.org/10.2119/molmed.2010.00180,.*inability to cross the blood.brain barrier.*, The failure of amlodipine to lower Aβ levels in vivo despite its ability to lower Aβ in vitro may be related to its inability to cross the blood-brain barrier (BBB) compared with highly lipophilic DHPs such as nilvadipine and nitrendipine which accumulate in the brain (30),Pass,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,amlodipine,0
https://doi.org/10.1038/s41398-021-01492-7,.*inability to cross the blood.brain barrier.*," However, a short half-life and inability to cross the blood–brain barrier impair the therapeutic potential of BDNF [61]",Duplicate,-,BDNF,0
https://doi.org/10.1186/1756-6606-6-50,.*does not penetrate the blood.brain barrier.*," Initially, the role of angiotensin II in the brain was not appreciated because angiotensin II does not penetrate the blood–brain barrier (BBB)",Pass,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N,angiotensin II,0
https://doi.org/10.1186/1471-2407-14-745,.*does not cross the blood.brain barrier.*," In addition, astemizole offers other advantages, such as the fact that it is a low-priced drug currently prescribed for treatment of simple allergic conditions or malaria in some countries and particularly because it does not cross the blood–brain barrier [33]",Pass,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,astemizole,0
https://doi.org/10.1038/s41380-021-01044-x,.*does not cross the blood.brain barrier.*," At this dose Dex does not cross the blood-brain barrier and acts predominantly in the periphery [26] Here, the most important site of action in relation to HPA axis function, especially when combined with a challenge with the neuropeptide CRH, is the pituitary",Fail,-,,
https://doi.org/10.1038/s41380-021-01044-x,.*does not cross the blood.brain barrier.*," Secondly, PVN Fkbp5 overexpression dramatically affects GR sensitivity and feedback at the level of the pituitary, as demonstrated by the inability of a low Dex dose (that does not cross the blood-brain barrier and acts predominantly at the level of the pituitary [26]) to suppress corticosterone secretion",Fail,-,,
https://doi.org/10.1186/s12967-019-2046-5,.*does not cross the blood.brain barrier.*," In rats with portacaval shunts, a model of MHE, reducing selectively peripheral inflammation by treating them with anti-TNFa, which does not cross the blood–brain barrier, prevents the induction of cognitive and motor alterations [9, 10]",Pass,-,anti-TNFa,0
https://doi.org/10.1186/s13023-021-01903-4,.*inability to cross the blood.brain barrier.*," Due to its inability to cross the blood–brain barrier, this drug can only be administered intrathecally through lumbar puncture",Fail,-,,
https://doi.org/10.1007/s11906-015-0550-4,.*unable to penetrate the blood.brain barrier.*," However, how circulating Ang II exerts central actions has long been under debate, owing to the fact that under normal physiological conditions, Ang II is unable to penetrate the blood brain barrier (BBB)",Duplicate,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N,Ang II,0
https://doi.org/10.1007/s11011-020-00539-w,.*does not cross the blood.brain barrier.*," Anti-TNF-α, which does not cross the blood–brain barrier, prevents hyperammonemia-induced neuroinflammation, alterations in microglial activation and cognitive impairment",Pass,-,Anti-TNF-alpha,0
https://doi.org/10.1186/s13024-020-00366-8,.*does not cross the blood.brain barrier.*," Although apoE is also produced by the liver and peripheral tissue macrophages, findings from liver transplant patients showed that apoE does not cross the blood-brain barrier and, as such, the brain and plasma pools of apoE are distinct [54]",Pass,-,apoE,0
https://doi.org/10.1038/s41598-018-22787-8,.*does not cross the blood.brain barrier.*," Unlike propranolol, atenolol is hydrophilic and does not cross the blood-brain barrier",Pass,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,atenolol,0
https://doi.org/10.1007/s00213-020-05693-8,.*does not cross the blood.brain barrier.*," In contrast to L-DOPA, carbidopa does not cross the blood-brain barrier and thus only acts on the periphery of the body",Duplicate,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,carbidopa,0
https://doi.org/10.1007/s12035-020-02266-w,.*unable to cross the blood.brain barrier.*, These drugs were shown to have lower log P values (CNS penetration ability) and hence were unable to cross the blood-brain barrier,Fail,-,,
https://doi.org/10.1186/s13075-015-0597-2,.*does not cross the blood.brain barrier.*," The anti-inflammatory action of these muscarinic agonists was blocked by centrally acting muscarinic antagonists but not by atropine methyl nitrate, which does not cross the blood–brain barrier [8]",Pass,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[N+](=O)([O-])[O-],atropine methyl nitrate,0
https://doi.org/10.1007/s00234-021-02643-9,.*does not cross the blood.brain barrier.*, It does not cross the blood-brain barrier and has to be administered intrathecally,Fail,-,,
https://doi.org/10.1007/s40265-021-01486-1,.*does not cross the blood.brain barrier.*," Further limitations of ERT are: (1) the short half-life, which results in short therapy intervals; (2) limited accessibility to specific tissues (does not cross the blood-brain barrier); (3) the difficult clearance of clinically relevant renal (podocytes) and cardiac cells (cardiomyocytes) compared to the endothelium; and (4) the high immunogenicity",Duplicate,CC[C@]1(C[C@@H](C2=C([C@H]1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N(C)C)O,ERT,0
https://doi.org/10.1007/s10295-015-1686-6,.*inability to cross the blood.brain barrier.*," While avermectin can bind GABA receptors in the mammalian central nervous system, the pharmacological effectiveness of the drug is owed to its inability to cross the blood–brain barrier [160, 161]",Pass,CCC(C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,avermectin,0
https://doi.org/10.1038/s41531-018-0066-0,.*does not cross the blood.brain barrier.*," Leads were exteriorized, prior to suturing the abdominal laparotomy; the jugular vein was catheterized to permit systemic administration of bethanechol (10 µg/kg), a muscarinic agonist that does not cross the blood-brain barrier and excites the smooth muscle directly supramaximally",Pass,CC(C[N+](C)(C)C)OC(=O)N,bethanechol,0
https://doi.org/10.1038/s42003-021-01666-5,.*unable to penetrate the blood.brain barrier.*," Furthermore, current KMO inhibitors possess a carboxylic acid group and are thought to be unable to penetrate the blood-brain barrier18,23,25",Fail,-,,
https://doi.org/10.1038/s41598-021-81832-1,.*inability to cross the blood.brain barrier.*," Whole brain irradiation has significant toxicity5 and cytotoxic chemotherapy has a limited role due to its inability to cross the blood–brain barrier5,6",Fail,-,,
https://doi.org/10.1186/s13023-020-01644-w,.*does not cross the blood.brain barrier.*,"Enzyme replacement therapy (ERT) with Laronidase (available since 2003) has shown to alter somatic disease symptoms and disease progression, but as it does not cross the blood brain barrier, this treatment option alone does not address the progressive central nervous system (CNS) decline [14, 15]",Duplicate,CC[C@]1(C[C@@H](C2=C([C@H]1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N(C)C)O,ERT,0
https://doi.org/10.1186/s12974-021-02249-1,.*does not penetrate the blood.brain barrier.*, AZA is absorbed rapidly through the GI system and does not penetrate the blood-brain barrier,Pass,-,AZA,0
https://doi.org/10.1186/s13256-020-02615-2,.*unable to cross the blood.brain barrier.*, Complicating the problem is the fact that most cytotoxic agents are unable to cross the blood brain barrier and therefore are expected to have limited activity in controlling brain metastases,Fail,-,,
https://doi.org/10.1186/s13054-014-0610-1,.*does not cross the blood.brain barrier.*, The mechanism for this is unclear but is most likely to be a peripheral vascular effect because atenolol is hydrophilic and does not cross the blood-brain barrier,Duplicate,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,atenolol,0
https://doi.org/10.1016/S0893-133X(99)00126-8,.*does not cross the blood.brain barrier.*,"Rats were pre-treated with atenolol, a β1-selective adrenergic antagonist which does not cross the blood brain barrier, to study the relative contribution of sympathetic and vagal outflow to CRH-induced cardiac changes",Duplicate,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,atenolol,0
https://doi.org/10.1186/s13569-020-00147-3,.*unable to cross the blood.brain barrier.*," Additionally, albumin administration to provide binding sites that are unable to cross the blood brain barrier, and haemodialysis, have been found to be effective [2]",Fail,-,,
https://doi.org/10.1038/s41598-021-93271-z,.*inability to cross the blood.brain barrier.*," However, the therapeutic potential of BDNF is restricted due to its short half-life (< 10 min) and inability to cross the blood–brain barrier (BBB) because of its large size (27 kDa)",Pass,-,BDNF,0
https://doi.org/10.1038/s41598-020-77193-w,.*does not penetrate the blood.brain barrier.*, The prolonged survival of IOPD patients raises a concern regarding central nervous system (CNS) involvement in IOPD11–13 because rhGAA does not penetrate the blood–brain barrier,Duplicate,-,rhGAA,0
https://doi.org/10.1038/s41598-020-77061-7,.*unable to cross the blood.brain barrier.*," We chose this specific antagonist because it is unable to cross the blood–brain barrier65, and therefore its consequences on VNO activity could be unequivocally assigned to direct manipulation of the sensory interface",Fail,-,,
https://doi.org/10.1007/s12035-020-02045-7,.*inability to pass through the blood.brain barrier.*," It is recognized that much of the ineffectiveness of CNS drug therapies can be traced from their inability to pass through the blood–brain barrier (BBB) [4, 5] and more importantly to reach their specific target cells within the brain, such as neurons or glial cells [6, 7]",Fail,-,,
https://doi.org/10.1038/mi.2013.52,.*does not cross the blood.brain barrier.*," Atropine methyl nitrate (AMN, a mAChR antagonist that does not cross the blood–brain barrier) (4 mg kg−1, intraperitoneal (IP) for 6 days) or atropine sulfate (AS, a mAChR antagonist that crosses the blood–brain barrier) were administered as a single daily injection 20 min before every GAL administration (4 mg kg−1, IP, for 6 days)",Duplicate,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[N+](=O)([O-])[O-],Atropine methyl nitrate,0
https://doi.org/10.1203/00006450-200207000-00011,.*does not cross the blood.brain barrier.*," The findings of the present study suggest that the second-order nucleus tractus solitarius sensory neurons that receive excitatory inputs from carotid bodies project to the rostral portion of the DMV, because blockade of muscarinic receptors by atropine methylnitrate, a drug that does not cross the blood-brain barrier, inhibited the hypoxia-induced increase in LES pressure",Duplicate,C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[N+](=O)([O-])[O-],atropine methylnitrate,0
https://doi.org/10.1038/s42003-020-01286-5,.*unable to cross the blood.brain barrier.*," A number of Notum inhibitors have been identified recently, however these molecules are unable to cross the blood-brain barrier22–24",Fail,-,,
https://doi.org/10.1186/s10194-019-1005-0,.*unable to cross the blood.brain barrier.*," have found that systemic injection of progesterone, AP, and other γ-aminobutyric acid-mimetic neurosteroids inhibits neurogenic edema in the rat meninges, and this effect is blocked by bicuculline, a γ-aminobutyric acid A receptor antagonist that is unable to cross the blood-brain barrier [24]",Pass,CN1CCC2=CC3=C(C=C2[C@H]1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,bicuculline,0
https://doi.org/10.1038/cddis.2012.59,.*does not cross the blood.brain barrier.*,"8, 11, 12 Because bFGF does not cross the blood–brain barrier after intravenous injection,16 we used intravenous administration of bFGF as a pharmacological approach to determine whether inhibiting apoptosis of endothelial cells by bFGF resulted in attenuation of the apoptotic response of NPCs in the dentate gyrus",Pass,-,bFGF,0
https://doi.org/10.1186/s40902-016-0051-7,.*does not cross the blood.brain barrier.*, BTX-A is considered relatively safe since it does not cross the blood-brain barrier with its effects localized in the peripheral sensory nerves [15],Pass,C[C@H](C1=CCC23[C@@]1(C[C@H](C4=C2C=CO4)OCOC)CN(CCO3)C)OC(=O)C5=CC=CC6=CC=CC=C65,BTX-A,0
https://doi.org/10.1007/s00401-020-02248-1,.*inability to penetrate the blood.brain barrier.*," When given systemically, BDNF administration is hindered by its inability to penetrate the blood–brain barrier and its incredibly short half-life [30]",Duplicate,-,BDNF,0
https://doi.org/10.1186/s42466-020-00075-z,.*does not cross the blood.brain barrier.*," Since the ASO generation available today does not cross the blood-brain barrier, the application must be carried out by intrathecal injection in the case of CNS disorders",Fail,-,,
https://doi.org/10.1186/s12974-020-01929-8,.*does not cross the blood.brain barrier.*," These data suggest peripherally administered miR-155 inhibitor has an effect on bone marrow-derived leukocytes entering the brain during infection, but does not directly affect microglia, likely because it does not cross the blood-brain barrier as suggested by the manufacturer’s product information [46]",Fail,-,,
https://doi.org/10.1038/s41598-021-81768-6,.*inability to cross the blood.brain barrier.*," However, BDNF use is limited in clinical practice because its short in vivo half-life and its inability to cross the blood–brain barrier7",Duplicate,-,BDNF,0
https://doi.org/10.1007/s11418-020-01431-8,.*unable to cross the blood.brain barrier.*," However, high-molecular weight proteins are unable to cross the blood–brain barrier and are easily decomposed by peptidase under physiological conditions",Fail,-,,
https://doi.org/10.1007/s00335-019-09793-5,.*unable to cross the blood.brain barrier.*," However, direct administration of BDNF is not a feasible treatment option because it is unable to cross the blood–brain barrier (BBB)",Duplicate,-,BDNF,0
https://doi.org/10.1038/s41467-018-06675-3,.*inability to cross the blood.brain barrier.*," This may have significant therapeutic implications as the application of exogenous BDNF is not clinically practical due to its instability in the bloodstream and its inability to cross the blood–brain barrier, and genetic intervention on human subjects may carry ethical issues",Duplicate,-,BDNF,0
https://doi.org/10.1038/npp.2014.232,.*does not cross the blood.brain barrier.*, BDNF itself is not practical as a therapy because it does not cross the blood–brain barrier,Duplicate,-,BDNF,0
https://doi.org/10.1007/s00415-020-09929-7,.*does not cross the blood.brain barrier.*," A series of case reports have reported that COVID-19 patients presenting with headache, altered mental status, acute CVD, acute necrotizing hemorrhagic encephalopathy, and acute Guillain–Barré syndrome but without abnormal cerebrospinal fluid (CSF) analysis, which indicates that SARS-CoV-2 does not cross the blood–brain barrier (BBB) and does not cause meningitis or encephalitis [14–18, 39, 40]",Fail,-,,
https://doi.org/10.1186/1750-1326-6-71,.*does not cross the blood.brain barrier.*," To date, there are no successful systems for delivering BDNF, because it does not cross the blood-brain barrier via peripheral administration [43, 44]",Duplicate,-,BDNF,0
https://doi.org/10.1038/sj.npp.1301615,.*does not penetrate the blood.brain barrier.*," As BDNF does not penetrate the blood–brain barrier and therapeutic administration of BDNF can be applied only through invasive techniques, memantine and other similarly acting agents may open new possibilities to regulate the expression of neurotrophic factors in the diseased brain",Duplicate,-,BDNF,0
https://doi.org/10.1007/s00018-019-03430-9,.*does not cross the blood.brain barrier.*," While glucose is readily absorbed by cells from the blood, fatty acid transport is coupled to albumin, which does not cross the blood brain barrier, limiting lipid availability in the brain [153]",Fail,-,,
https://doi.org/10.1007/s11912-020-00941-8,.*inability to penetrate the blood.brain barrier.*," The treatment regimen most commonly used in systemic DLBCL, R-CHOP chemotherapy, has been shown to be ineffective in PCNSL, likely because of its inability to penetrate the blood-brain barrier (BBB) [11]",Fail,-,,
https://doi.org/10.1038/s41467-020-16832-2,.*inability to penetrate the blood.brain barrier.*," Systemic treatments, such as chemotherapies or targeted therapies, cannot effectively treat micrometastatic brain lesions or prevent brain metastatic relapse, largely due to their inability to penetrate the blood–brain barrier (BBB)1",Fail,-,,
https://doi.org/10.1007/s11064-019-02901-6,.*unable to cross the blood.brain barrier.*," For example, the SAS analogues characterized here are of limited therapeutic value for inhibiting Sxc− in glioblastoma cells, owing to the presence of functional groups that are necessary to interact with the substrate binding domains, but generally render the compounds unable to cross the blood brain barrier [13]",Fail,-,,
https://doi.org/10.1007/s00702-020-02180-4,.*unable to penetrate the blood.brain barrier.*," However, although all the abovementioned NET-targeting radiotracers can be used for peripheral SNS imaging, they are unable to penetrate the blood–brain barrier (BBB), most probably due to their polar structures with guanidine moieties",Fail,-,,
https://doi.org/10.1186/s13048-020-00655-2,.*unable to cross the blood.brain barrier.*," Such tendency may be explained with the improvement of chemotherapeutic agents, able to contrast typical routes of metastatic spread, though unable to cross the blood-brain barrier (BBB) [29]",Fail,-,,
https://doi.org/10.1007/s40263-020-00722-8,.*unable to pass through the blood.brain barrier.*," If a vaccinated subject is exposed to the targeted opioid, the antibodies should bind to the target opioid, generating an antibody-opioid complex that should be unable to pass through the blood–brain barrier",Fail,-,,
https://doi.org/10.1007/s40272-019-00344-8,.*does not cross the blood.brain barrier.*, BoNT does not cross the blood–brain barrier,Pass,-,BoNT,0
https://doi.org/10.1038/s41598-020-62923-x,.*does not cross the blood.brain barrier.*,"The use of CNO to activate DREADDS has become controversial since the discovery that CNO does not cross the blood–brain barrier and that activation of DREADDs in vivo is likely mediated by the conversion of CNO to CLZ4,6,29",Duplicate,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],CNO,0
https://doi.org/10.1186/1471-2407-13-204,.*does not cross the blood.brain barrier.*,"For these studies, we chose bethanechol, a non-selective muscarinic agonist because it lacks nicotinic receptor activity, is commonly used in murine studies of salivation and neurological function [13–15], does not cross the blood–brain barrier, has excellent short- and long-term safety profiles in mice [16, 17], and is FDA-approved (trade name Duvoid) for treatment of urinary retention and atony of the urinary bladder",Duplicate,CC(C[N+](C)(C)C)OC(=O)N,bethanechol,0
https://doi.org/10.1007/s42452-020-2402-3,.*does not cross the blood.brain barrier.*," Because it does not cross the blood–brain barrier, sedation or other central nervous system effects don’t occur [12]",Fail,-,,
https://doi.org/10.1038/s41467-020-15277-x,.*does not cross the blood.brain barrier.*," This dose of clozapine has previously been shown to produce comparable effects to those commonly used for the original DREADD activator (10 mg/kg), which does not cross the blood brain barrier and therefore requires metabolic conversion to clozapine in order to act centrally45",Fail,-,,
https://doi.org/10.1007/s00213-020-05693-8,.*does not cross the blood.brain barrier.*," In contrast to L-DOPA, carbidopa does not cross the blood-brain barrier and thus only acts on the periphery of the body",Pass,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,carbidopa,0
https://doi.org/10.1007/s00415-020-09705-7,.*does not cross the blood.brain barrier.*," However, as in the case of the currently approved substrate reduction therapies, ERT does not cross the blood–brain barrier and does cannot affect the neurological symptoms found in GD Type II and III",Duplicate,CC[C@]1(C[C@@H](C2=C([C@H]1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N(C)C)O,ERT,0
https://doi.org/10.1007/s00125-012-2654-6,.*does not cross the blood.brain barrier.*," CCK-8 does not cross the blood–brain barrier [2], making accumulation in the brain unlikely even following repeated dosing",Pass,CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N,CCK-8,0
https://doi.org/10.1203/00006450-200205000-00005,.*inability to cross the blood.brain barrier.*," The efficacies of SOD and catalase are limited by their inability to cross the blood-brain barrier and penetrate cells (21, 26)",Pass,-,catalase,0
https://doi.org/10.1038/s41583-020-0333-z,.*does not cross the blood.brain barrier.*," However, CBX does not cross the blood–brain barrier91 and is therefore likely to act largely in the periphery, and gap junction blockers did not affect the withdrawal threshold in control mice",Pass,-,CBX,0
https://doi.org/10.1186/s12974-018-1274-6,.*does not cross the blood.brain barrier.*," These results suggest that cefazolin does not cross the blood-brain barrier, consistent with previous findings [24, 25]",Pass,CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O,cefazolin,0
https://doi.org/10.1007/s12672-021-00423-8,.*inability to cross the blood.brain barrier.*, The low numbers of CD8+TILs might be related to their inability to cross the blood–brain barrier efficiently,Pass,-,CD8+TIL,0
https://doi.org/10.1007/s12035-021-02521-8,.*does not cross the blood.brain barrier.*," Nevertheless, cholesterol itself does not cross the blood–brain barrier (BBB), posing the question of how plasma hypercholesterolemia is linked to the risk of developing AD",Pass,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,cholesterol,0
https://doi.org/10.1038/s41598-019-55136-4,.*does not cross the blood.brain barrier.*," However, for most disorders, no intravenous (IV) Enzyme Replacement Therapy (ERT) has been developed because (a) the primary clinical manifestations of the disease are CNS, and (b) the recombinant enzyme does not cross the blood-brain barrier (BBB)",Fail,-,,
https://doi.org/10.1038/s41598-019-55150-6,.*inability to cross the blood.brain barrier.*, Cytotoxic chemotherapy (CC) plays a limited role in the treatment of brain metastasis because of the agents’ inability to cross the blood–brain barrier (BBB)5,Fail,-,,
https://doi.org/10.1186/1471-2202-7-3,.*does not penetrate the blood.brain barrier.*,Our results suggest that CBX does not penetrate the blood brain barrier after i,Duplicate,-,CBX,0
https://doi.org/10.1186/s40360-019-0367-x,.*does not cross the blood.brain barrier.*," Preclinical evidence suggests that the agent does not cross the blood–brain barrier (BBB) to a significant extent [15, 26]",Fail,-,,
https://doi.org/10.1203/00006450-199809000-00001,.*does not cross the blood.brain barrier.*,"Ceruloplasmin does not cross the blood-brain barrier, and this implies that any direct role for this protein in CNS iron metabolism must involve expression within this site",Pass,-,Ceruloplasmin,0
https://doi.org/10.1186/s12974-019-1619-9,.*does not cross the blood.brain barrier.*," Interestingly, these areas are intimately in contact with the cerebrospinal fluid (CSF), and although it is generally believed that paclitaxel does not cross the blood-brain barrier, low concentrations of paclitaxel can be detected in spinal cord tissue and CSF [24, 25]",Fail,-,,
https://doi.org/10.1038/s41436-019-0522-1,.*unable to penetrate the blood.brain barrier.*," Intravenous ERT is presumed to be unable to penetrate the blood–brain barrier to treat the CNS manifestations of Hurler syndrome,8,14 but it is used as an adjunct to HCT to decrease morbidity and mortality",Duplicate,CC[C@]1(C[C@@H](C2=C([C@H]1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N(C)C)O,ERT,0
https://doi.org/10.1186/1752-1947-2-320,.*does not cross the blood.brain barrier.*, Cetuximab does not cross the blood brain barrier and may select a metastatic clone to home the central nervous system while responding at other sites,Pass,-,Cetuximab,0
https://doi.org/10.1007/s10194-008-0036-8,.*unable to cross the blood.brain barrier.*, This indicated that CGRP was unable to cross the blood–brain barrier in rat MCA,Pass,-,CGRP,0
https://doi.org/10.1038/s41598-018-19592-8,.*does not cross the blood.brain barrier.*,"Because CHOL does not cross the blood-brain barrier (see Discussion), it is not unexpected to see that the levels of CHOL and 7DHC in different brain regions were not significantly affected in animals fed a CHOL-enriched (AY2 and AY3) diet (Supplementary Material, Fig",Pass,-,CHOL,0
https://doi.org/10.1007/s12094-019-02071-5,.*inability to cross the blood.brain barrier.*," Treatment options for CNS metastases during or after first- or second-generation EGFR-TKIs include surgical resection, stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT) and chemotherapy, but with severe adverse effects or limited inability to cross the blood–brain barrier (BBB) [8–11]",Fail,-,,
https://doi.org/10.1038/s41467-019-11962-8,.*does not cross the blood.brain barrier.*," ERT does not cross the blood–brain barrier, requires costly life-long infusions, and inhibitory antibodies can further decrease enzyme bioavailability2",Fail,-,,
https://doi.org/10.1038/s41467-017-01837-1,.*does not cross the blood.brain barrier.*," Platinum levels in brain remained very low, consistent with reports that cisplatin does not cross the blood–brain barrier22,23",Pass,N.N.Cl[Pt]Cl,cisplatin,0
https://doi.org/10.1186/s12879-019-4408-2,.*does not cross the blood.brain barrier.*," Moreover, clindamycin does not cross the blood-brain barrier making it impractical for the treatment of intracranial actinomycosis",Pass,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,clindamycin,0
https://doi.org/10.1038/s41598-017-01047-1,.*inability to cross the blood.brain barrier.*," β3-AR expression in the brain is low33 and central receptors are not reached by systemically administered CL-316,243 due to its inability to cross the blood-brain barrier34",Pass,-,CL-316,0
https://doi.org/10.1038/s41598-020-62923-x,.*does not cross the blood.brain barrier.*," However, recent evidence shows that CNO does not cross the blood−brain barrier and may in fact have low binding affinity for DREADDs4",Pass,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],CNO,0
https://doi.org/10.1038/s41598-021-83008-3,.*does not cross the blood.brain barrier.*," In the brain, cholesterol is synthesized entirely in situ by astrocytes, and peripheral cholesterol does not cross the blood–brain barrier (BBB) under physiological conditions12",Duplicate,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,cholesterol,0
https://doi.org/10.1038/s41380-020-0801-x,.*does not cross the blood.brain barrier.*,"Cholesterol does not cross the blood–brain barrier, and cholesterol obtained from the diet or synthesized by the liver and various somatic cells does not contribute to the brain cholesterol pool",Duplicate,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,Cholesterol,0
https://doi.org/10.1186/s42466-019-0026-0,.*does not penetrate the blood.brain barrier.*,"BBB Blood brain barrier, MS Multiple sclerosis, OPC Oligodendroglial precursor cell, PTH Parathyroid hormone, MOG Myelin oligodendrocyte glycoprotein, PLP Proteolipid protein, EAE Experimental autoimmune encephalomyelitis, NMO Neuromyelitis optica, MP4 MBP-PLP fusion protein, NOD Non-obese diabetes, OTC Over the counter, + = penetrates the blood brain barrier, (+) = only little evidence for BBB penetration or low permeability, − = does not penetrate the blood brain barrier, * = Anti-NogoA antibody was administered intravenously in clinical trials with MS patients, but pharmacokinetic data was not publicly accessibleFig",Fail,-,,
https://doi.org/10.1186/s40478-016-0370-z,.*does not cross the blood.brain barrier.*," The role of NPC1/NPC2 proteins is particularly important in neural cells because cholesterol does not cross the blood–brain barrier once it is fully established after birth [5], making the adult brain mostly dependent on endogenously-derived cholesterol",Duplicate,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,cholesterol,0
https://doi.org/10.1038/srep28534,.*does not cross the blood.brain barrier.*," Importantly, cholesterol does not cross the blood-brain barrier and thus the contribution of maternal cholesterol to central nervous system drops from E10-11 onwards, being 90% of neonatal brain cholesterol of embryonic origin29",Duplicate,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,cholesterol,0
https://doi.org/10.1186/1471-2407-14-449,.*does not cross the blood.brain barrier.*," Even if TMZ in experimental animal models is typically given orally, here we have chosen to administer it via an intracranial route to allow direct comparison with CNF1, which does not cross the blood–brain barrier",Pass,-,CNF1,0
https://doi.org/10.1007/s00213-017-4593-x,.*does not cross the blood.brain barrier.*," For example, cocaine methiodide, a quaternary cocaine analogue that does not cross the blood-brain barrier, only gains reinforcing properties in rats with a history of cocaine self-administration (Wang et al",Pass,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-],cocaine methiodide,0
https://doi.org/10.1038/s41598-019-44006-8,.*does not cross the blood.brain barrier.*," Although a low dose of LPS does not cross the blood-brain barrier (BBB)4,5, activation of microglia in the central nervous system (CNS) is observed in peripherally LPS-treated models6",Fail,-,,
https://doi.org/10.1186/s12917-019-1878-9,.*does not cross the blood.brain barrier.*," It normally does not cross the blood brain barrier due to its relative high molecular weight of 450 kD [60], and no correlation between CSF and serum ferritin concentration has been found in people",Fail,-,,
https://doi.org/10.1186/1750-1326-8-6,.*does not cross the blood.brain barrier.*," While Congo red does not cross the blood brain barrier, it will cross living cell membranes and label intracellular amyloidal aggregates in vitro [16, 17]",Pass,C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])N)S(=O)(=O)[O-].[Na+].[Na+],Congo red,0
https://doi.org/10.1038/s41467-017-01881-x,.*does not cross the blood.brain barrier.*," Second, using a cocaine analog (cocaine methiodide) that does not cross the blood-brain barrier, we tested the effects of increased peripheral cocaine on central and peripheral G-CSF levels",Duplicate,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-],cocaine methiodide,0
https://doi.org/10.1038/npp.2015.230,.*does not cross the blood.brain barrier.*," Cocaine MI is a synthetic cocaine analog that does not cross the blood–brain barrier but that can serve as a conditioned reinforcer in cocaine-trained animals (Wang et al, 2013)",Pass,-,Cocaine MI,0
https://doi.org/10.1007/s13311-020-00897-4,.*does not cross the blood.brain barrier.*," Darifenacin does not cross the blood–brain barrier and is selective for M3 receptors, which are primarily located in the bladder",Pass,C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5,Darifenacin,0
https://doi.org/10.1038/jhh.2014.103,.*does not cross the blood.brain barrier.*," The elevation of blood pressure by cocaine methiodide, a quaternary cocaine derivative that does not cross the blood–brain barrier, by 30–80% in rats36 and 10% by dobutamine in humans37 was not associated with changes in the global BOLD signal",Duplicate,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-],cocaine methiodide,0
https://doi.org/10.1038/npp.2013.75,.*does not cross the blood.brain barrier.*," We used cocaine methiodide, a cocaine analog that does not cross the blood–brain barrier, to isolate the peripheral actions of cocaine and determine their central and behavioral effects in animals first trained to lever-press for cocaine hydrochloride (the centrally acting and abused form of the drug)",Duplicate,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-],cocaine methiodide,0
https://doi.org/10.1186/s12888-021-03443-4,.*does not cross the blood.brain barrier.*," Under normal conditions, CRP does not cross the blood-brain barrier",Pass,-,CRP,0
https://doi.org/10.1038/npp.2013.75,.*does not cross the blood.brain barrier.*,"Our primary findings were that a peripheral action of cocaine—triggered selectively by cocaine MI, a cocaine analog that does not cross the blood–brain barrier—activates the reward system and serves as a conditioned reinforcer in cocaine-experienced but not cocaine-naive rats",Duplicate,-,cocaine MI,0
https://doi.org/10.1038/s41598-017-11664-5,.*does not penetrate the blood.brain barrier.*," However, neuroprotective efficacy of dipyridamole in human patients appears unlikely, since it does not penetrate the blood-brain barrier",Pass,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,dipyridamole,0
https://doi.org/10.1186/s40673-017-0062-x,.*does not cross the blood.brain barrier.*,"Desferoxamine, a widely used iron chelator for iron overload conditions does not cross the blood brain barrier",Pass,-,Desferoxamine,0
https://doi.org/10.1038/s42003-020-01570-4,.*does not cross the blood.brain barrier.*," To acutely elevate PRL levels, we performed an intraperitoneal injection of the D2 dopamine receptor antagonist domperidone, which does not cross the blood–brain barrier50,51, and measured PRL levels 15 min after the procedure",Pass,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1007/s40265-018-1033-0,.*does not cross the blood.brain barrier.*," Some preclinical studies suggest that telotristat etiprate does not cross the blood-brain barrier ([Lexicon, unpublished observations in [18])",Fail,-,,
https://doi.org/10.1038/s41598-021-00764-y,.*does not cross the blood.brain barrier.*," Although dopamine does not cross the blood–brain barrier, its immediate precursor, levodopa, is actively transported into the central nervous system and converted to dopamine in the brain7",Pass,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1007/s00018-013-1509-8,.*does not penetrate the blood.brain barrier.*," As desferrioxamine does not penetrate the blood–brain barrier, this drug has obvious limitations for treatment inside the CNS, but it might be valuable for chelation of iron extracellularly in the brain, in particular in pathological conditions with a perturbed blood–brain barrier",Duplicate,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O,desferrioxamine,0
https://doi.org/10.1038/s41398-018-0318-0,.*unable to cross the blood.brain barrier.*," The drug binds to plasma proteins, which impairs its entry into the brain, as plasma proteins are unable to cross the blood–brain barrier33",Fail,-,,
https://doi.org/10.1186/1472-6815-12-4,.*does not cross the blood.brain barrier.*, Dexamethasone is a synthetic glucocorticoid with high GR receptor affinity that does not cross the blood-brain barrier [27–29],Duplicate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,Dexamethasone,0
https://doi.org/10.1186/s13052-018-0566-x,.*does not cross the blood.brain barrier.*,The major limitation of ERT for MPS is that it does not cross the blood–brain barrier preventing any effect on the central nervous system (CNS) in severely affected patients who show cognitive involvement (see Concolino et al,Fail,-,,
https://doi.org/10.1186/s13052-018-0562-1,.*does not cross the blood.brain barrier.*," ERT in the present formulations also does not cross the blood–brain barrier, with the consequence that the central nervous system is not cured by ERT",Fail,-,,
https://doi.org/10.1186/s41016-021-00238-0,.*inability to penetrate the blood.brain barrier.*, Doxorubicin is not included in regimens for treating PCNSL because of its inability to penetrate the blood-brain barrier [8],Pass,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,Doxorubicin,0
https://doi.org/10.1007/s11894-018-0664-3,.*does not penetrate the blood.brain barrier.*," From the historical use of opioids with both peripheral and central effects, the advent of loperamide, a μ-receptor agonist that does not penetrate the blood-brain barrier was a major break-through",Fail,-,,
https://doi.org/10.1186/s13023-016-0413-3,.*does not cross the blood.brain barrier.*, Eliglustat does not cross the blood brain barrier,Pass,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O,Eliglustat,0
https://doi.org/10.1007/s13311-020-00897-4,.*does not cross the blood.brain barrier.*," Domperidone also is dopamine antagonist but does not cross the blood–brain barrier, rendering it acceptable for use in PD",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,Domperidone,0
https://doi.org/10.1007/s40263-019-00661-z,.*does not cross the blood.brain barrier.*," [27] showed that nausea deriving from apomorphine injections could be controlled via the administration of domperidone, a peripheral dopamine antagonist that does not cross the blood–brain barrier",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1186/s12883-018-1230-1,.*does not cross the blood.brain barrier.*," Since domperidone, a D2-receptor antagonist which does not cross the blood-brain barrier, can completely block the hypotensive effects and partially block the bradycardia effects of piribedil, this may indirectly confirm that the bradycardic effect of piribedil is via central action to some extent [21, 22]",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1038/s41598-018-33395-x,.*unable to penetrate the blood.brain barrier.*," A very unfortunate situation, as medicals unable to penetrate the blood-brain barrier (suramin, pentamidine) are far less toxic than those entering the brain (melarsoprol B, eflornithine)",Fail,-,,
https://doi.org/10.1007/s13311-017-0592-1,.*does not cross the blood.brain barrier.*," However, domperidone has the advantage of not causing extrapyramidal side effects, as it does not cross the blood–brain barrier",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1186/s13023-016-0522-z,.*does not cross the blood.brain barrier.*," Although domperidone is a dopamine antagonist, it does not cross the blood brain barrier and therefore side-effects in AADCD are expected to be limited",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1186/s40064-015-1206-1,.*does not cross the blood.brain barrier.*," This case illustrates several important messages in migraine management: (1) use of acetaminophen is not based in high-quality evidence and better options exist; (2) among youngsters, domperidone should be preferred over metoclopramide because it does not cross the blood–brain barrier; (3) moderate to severe migraine crisis can be managed with triptans in teenagers over 12 years old; (4) it is important to recognize adverse drug effects; (5) harmful consequences of medical interventions do occur; (6) the school community must be informed about chronic diseases of the young",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1038/s41598-018-31680-3,.*unable to cross the blood.brain barrier.*, Several other compounds within this series were tested for brain penetration and were likewise unable to cross the blood brain barrier,Fail,-,,
https://doi.org/10.1007/s40263-014-0157-3,.*does not cross the blood.brain barrier.*," This hypothesis is supported by the observation that domperidone, a D2 blocker that does not cross the blood–brain barrier, is associated with significant PRL elevation [422]",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1007/s40263-013-0054-1,.*does not cross the blood.brain barrier.*," This effect is illustrated by the peripheral D2 antagonist domperidone: administration of this agent, which does not cross the blood-brain barrier except in rare cases of blood-brain barrier immaturity or disruption [74], significantly increases the release of both adrenal noradrenaline and adrenaline [75], and reverses the antihypertensive effect of dopaminergic drugs [76]",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1186/1477-7827-11-14,.*does not cross the blood.brain barrier.*, Domperidone is also a well-characterized DA D2 receptor antagonist that is not water-soluble and does not cross the blood–brain barrier [31],Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,Domperidone,0
https://doi.org/10.1186/s13023-018-0849-8,.*does not cross the blood.brain barrier.*, Recombinant IDUA does not cross the blood-brain barrier (BBB),Fail,-,,
https://doi.org/10.1186/s13023-018-0849-8,.*does not cross the blood.brain barrier.*," Laronidase has no impact on cognitive decline in MPSI [4], because the enzyme does not cross the blood-brain barrier (BBB) [5]",Fail,-,,
https://doi.org/10.1186/s13024-018-0266-4,.*does not cross the blood.brain barrier.*," Since systemic LPS does not cross the blood brain barrier [55], our observations are more likely to represent indirect effects of LPS (involving Tnf or other soluble factors) rather than direct toll-like-receptor-mediated effects of LPS on microglia [56]",Fail,-,,
https://doi.org/10.1038/s41598-018-27926-9,.*inability to cross the blood.brain barrier.*,"5% reaches the brain upon systemic administration due to its inability to cross the blood brain barrier (BBB)25,53",Fail,-,,
https://doi.org/10.1007/s00213-010-2087-1,.*does not cross the blood.brain barrier.*, Domperidone is a peripheral D2 antagonist that does not cross the blood–brain barrier (Champion 1988),Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,Domperidone,0
https://doi.org/10.1007/s00213-007-0941-6,.*does not cross the blood.brain barrier.*," However, it must be noted that domperidone does not cross the blood–brain barrier but exerts its effect peripherally, and as such, does not have a major influence on the central dopamine system (Barone 1999; Champion et al",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1186/s40478-021-01240-4,.*does not cross the blood.brain barrier.*," As DSS does not cross the blood–brain barrier, these effects were necessarily mediated by its activity in the periphery [78]",Pass,-,DSS,0
https://doi.org/10.1038/s41413-021-00144-2,.*does not cross the blood.brain barrier.*,"16 Importantly, dopamine does not cross the blood–brain barrier; thus, intravenous administration does not deliver dopamine to the brain",Duplicate,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1186/s12933-018-0702-3,.*does not cross the blood.brain barrier.*," These peptides are not affected in samples from linagliptin-treated control mice, which is in line with the observation that linagliptin does not cross the blood brain barrier under physiological conditions [55]",Duplicate,CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C,linagliptin,0
https://doi.org/10.1038/s41467-018-05283-5,.*does not cross the blood.brain barrier.*," However, it is unlikely that this is a direct effect, as dopamine does not cross the blood brain barrier (BBB), raising the question of how the signal is transmitted from the brain to the tumor",Duplicate,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1186/s12929-018-0428-2,.*does not cross the blood.brain barrier.*," As dopamine does not cross the blood-brain barrier, therefore its administration is not possible, so levodopa bypassing this barrier may be rapidly decarboxylated and transformed by enzymes into dopamine, hence it becomes the choice of therapeutic drug administration in order to minimize cognitive and motor deficits resulting from low dopaminergic levels [71]",Duplicate,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1007/s00018-017-2691-x,.*inability to cross the blood.brain barrier.*,The key limitation of NTs in the treatment of PNS and CNS diseases is their inability to cross the blood–brain barrier,Fail,-,,
https://doi.org/10.1038/s41598-017-12422-3,.*does not cross the blood.brain barrier.*," Another study found no correlation between exercise-induced increases in systemic dopamine and improvements in motor learning32, but acknowledged that dopamine does not cross the blood-brain barrier in appreciable amounts and that systemic levels do not necessarily reflect cortical levels31",Duplicate,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1038/modpathol.2016.158,.*does not cross the blood.brain barrier.*," Because dopamine does not cross the blood–brain barrier, they hypothesized involvement of the sympathetic nervous system",Duplicate,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1038/srep11078,.*does not cross the blood.brain barrier.*, Dopamine as such does not cross the blood brain barrier whereas L-dopa does and in the central nervous system dopa decarboxylase converts it into dopamine,Duplicate,C1=CC(=C(C=C1CCN)O)O,Dopamine,0
https://doi.org/10.1038/s41598-018-22162-7,.*does not cross the blood.brain barrier.*, It chelates cholesterol but does not cross the blood brain barrier (BBB)26,Fail,-,,
https://doi.org/10.1007/s00702-017-1708-9,.*does not cross the blood.brain barrier.*," As 6-OHDA does not cross the blood–brain barrier (BBB), it is stereotaxically injected directly into the right or left striatum, medial forebrain bundle or substantia nigra, inducing unilateral motor impairments",Duplicate,C1=C(C(=CC(=C1O)O)O)CCN,6-OHDA,0
https://doi.org/10.1007/s00702-013-0981-5,.*does not cross the blood.brain barrier.*,Dopamine does not cross the blood–brain barrier,Duplicate,C1=CC(=C(C=C1CCN)O)O,Dopamine,0
https://doi.org/10.1203/00006450-199706000-00006,.*does not cross the blood.brain barrier.*," In adults, dopamine does not cross the blood-brain barrier(26), but this barrier develops gradually in children until about 6 mo of age(27)",Duplicate,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1038/s41440-021-00643-z,.*does not cross the blood.brain barrier.*," The selective APA inhibitor EC33 does not cross the blood-brain barrier; therefore, researchers have developed systemically active prodrugs",Pass,-,EC33,0
https://doi.org/10.1186/s40409-018-0139-x,.*unable to cross the blood.brain barrier.*," Because, they say, at least in adult individuals, the venom would be unable to cross the blood-brain barrier",Fail,-,,
https://doi.org/10.1186/s40409-018-0139-x,.*unable to cross the blood.brain barrier.*," According to Freire-Maia and Campos [31], the central effects would be the result and not the cause of the envenoming process, since the venom would be unable to cross the blood-brain barrier",Fail,-,,
https://doi.org/10.1007/s40089-014-0094-7,.*does not cross the blood.brain barrier.*," For example, doxorubicin does not cross the blood–brain barrier, but its integration with polysorbate 80 modified polybutylcyanoacrylate nanoparticles can increase its delivery to the brain to a significant extent [28]",Duplicate,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,doxorubicin,0
https://doi.org/10.1186/s13550-018-0358-8,.*does not cross the blood.brain barrier.*," Assuming that RG7356 does not cross the blood–brain barrier, this value is determined by the blood volume fraction of the brain",Fail,-,,
https://doi.org/10.1038/s41387-017-0015-8,.*inability to cross the blood.brain barrier.*," Natural anorexigenic neuropeptides have that potential, but their major disadvantage is their low stability in plasma and inability to cross the blood brain barrier (BBB) after peripheral administration",Fail,-,,
https://doi.org/10.1203/01.PDR.0000127012.37315.36,.*does not cross the blood.brain barrier.*," As enalaprilat does not cross the blood-brain barrier (31), the effects observed after systemic administration of this ACE-I represent the role of peripherally derived AngII on cardiovascular function",Pass,C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O,enalaprilat,0
https://doi.org/10.1038/s41467-017-01881-x,.*does not cross the blood.brain barrier.*," for 7 days with cocaine methiodide (CocMet), a cocaine analog that does not cross the blood brain barrier, to assess the effects of peripheral cocaine on G-CSF",Duplicate,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-],cocaine methiodide,0
https://doi.org/10.1038/s41467-017-01881-x,.*does not cross the blood.brain barrier.*," To this end, mice were injected daily with cocaine methiodide–a charged analog of cocaine that does not cross the blood-brain barrier25 (Fig",Duplicate,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-],cocaine methiodide,0
https://doi.org/10.1038/s41467-017-01881-x,.*does not cross the blood.brain barrier.*,To assess the effects of peripheral cocaine on expression of G-CSF in both the periphery and the CNS we utilized the charge cocaine analog cocaine methiodide—which does not cross the blood brain barrier25 to dissociate central vs,Duplicate,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-],cocaine methiodide,0
https://doi.org/10.1186/s12974-019-1580-7,.*does not cross the blood.brain barrier.*, DSS does not cross the blood–brain barrier because of its higher molecular weight,Duplicate,-,DSS,0
https://doi.org/10.1186/s12974-015-0281-0,.*does not cross the blood.brain barrier.*," DSS is a large molecule (molecular weight (MW) 30,000 to 50,000) that does not cross the blood-brain barrier",Duplicate,-,DSS,0
https://doi.org/10.1007/s13311-017-0598-8,.*does not cross the blood.brain barrier.*," [112] demonstrated that treating male and female Siberian hamsters with enrofloxacin, a broad-spectrum fluoroquinolone antibiotic that does not cross the blood–brain barrier, reduced aggression in both male and female mice [112]",Pass,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,enrofloxacin,0
https://doi.org/10.1203/PDR.0b013e3181fcbef3,.*does not cross the blood.brain barrier.*,It has been reported that EPO does not cross the blood-brain barrier in a detectable amounts when given at doses appropriate for erythropoiesis (200–400 U/kg) (32),Pass,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],EPO,0
https://doi.org/10.1186/s12871-015-0154-1,.*does not cross the blood.brain barrier.*," Esmolol, unlike propranolol [23], has no analgesic activity, is believed to have minimal sedative effects and given its low lipid solubility does not cross the blood–brain barrier in significant amounts [20, 24]",Pass,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,Esmolol,0
https://doi.org/10.1186/s13024-017-0227-3,.*inability to cross the blood.brain barrier.*, This is thought to be related to the small amount of growth factor that effectively reached the central nervous system (CNS) either because of an inability to cross the blood brain barrier or because of the short half-life after intravenous injection [112],Fail,-,,
https://doi.org/10.1186/s10194-021-01333-4,.*does not cross the blood.brain barrier.*," Erenumab is a large molecule that does not cross the blood brain barrier and therefore it is thought to directly act on peripheral sensitization [59, 60], even if it is not possible to totally exclude it may have additional central effects [61]",Pass,-,Erenumab,0
https://doi.org/10.1007/s10286-020-00714-0,.*does not cross the blood.brain barrier.*, Fenoldopam is a catechol-containing DRD1 partial agonist that does not cross the blood-brain barrier,Pass,C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O,Fenoldopam,0
https://doi.org/10.1186/s12868-019-0529-1,.*unable to penetrate the blood.brain barrier.*," Etanercept is such a large molecule that it is usually unable to penetrate the blood–brain barrier (BBB) [24], but the several studies have demonstrated that the BBB could be disrupted by LPS exposure [25, 26]",Pass,-,Etanercept,0
https://doi.org/10.1186/s41824-019-0071-5,.*does not cross the blood.brain barrier.*," In contrary to FDG, FLT does not cross the blood-brain barrier if intact (Nikaki et al",Pass,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)F,FLT,0
https://doi.org/10.1038/cddis.2012.59,.*does not cross the blood.brain barrier.*," Intravenous administration of basic fibroblast growth factor, which does not cross the blood–brain barrier, known to protect endothelial cells against apoptosis after irradiation also attenuated the apoptotic response of NPCs",Pass,-,fibroblast growth factor,0
https://doi.org/10.1007/s13311-016-0455-1,.*does not penetrate the blood.brain barrier.*, These findings are important given that etanercept does not penetrate the blood–brain barrier when administered systemically,Duplicate,-,etanercept,0
https://doi.org/10.1186/s10194-017-0811-5,.*unable to penetrate the blood.brain barrier.*," In line with this, few preclinical studies revealed that humanized CGRP mAb are (i) unable to penetrate the blood-brain barrier in the perfused MCA [77]; (ii) ineffective in inhibiting the responses to CGRP-induced neurogenic vasodilation of the pial artery [78]; and (iii) capable of inhibiting CGRP-induced neurogenic vasodilation of the MMA, which as mentioned above lacks blood-brain barrier [65, 79]",Fail,-,,
https://doi.org/10.1007/s13311-017-0570-7,.*unable to cross the blood.brain barrier.*,"Prevention of T cell entry into the central nervous system may preclude their function in the setting of natalizumab use, noting the leading theory for natalizumab-associated PML is that of decreased immunosurveillance—hypothesizing that when T cells are sequestered in the periphery and unable to cross the blood–brain barrier to reach JCV-infected cells the virus can propagate in brain tissue [69, 70]",Fail,-,,
https://doi.org/10.1186/1471-2377-8-27,.*does not cross the blood.brain barrier.*, Etanercept does not cross the blood-brain barrier when administered systemically [59],Duplicate,-,Etanercept,0
https://doi.org/10.1038/s41598-018-32733-3,.*does not pass through the blood.brain barrier.*, GABA does not pass through the blood-brain barrier (BBB) making it ill-suited to inhibit the spreading of autoreactivity within the CNS,Pass,C(CC(=O)O)CN,GABA,0
https://doi.org/10.1186/1471-2202-10-41,.*does not cross the blood.brain barrier.*," As the Fluorogold does not cross the blood-brain barrier, this procedure only labels cells in the brain that project to areas that come into contact with fenestrated capillaries [27]",Pass,-,Fluorogold,0
https://doi.org/10.1038/s41598-017-11302-0,.*inability to cross the blood.brain barrier.*, The most important reported reason for the failure of most inhibitors during the clinical trials was their inability to cross the blood-brain barrier to penetrate and distribute inside neurons,Fail,-,,
https://doi.org/10.1186/s13041-018-0401-8,.*does not cross the blood.brain barrier.*," Previous reports indicated that FNDC5 does not cross the blood brain barrier, suggesting that FNDC5 in the brain may not be derived from the peripheral tissue",Pass,-,FNDC5,0
https://doi.org/10.1038/gim.2016.223,.*does not cross the blood.brain barrier.*, The mechanism of attenuation is unclear because ERT does not cross the blood–brain barrier,Fail,-,,
https://doi.org/10.1186/s12936-017-1994-6,.*unable to cross the blood.brain barrier.*, Furthermore the drug is unable to cross the blood–brain barrier [21],Fail,-,,
https://doi.org/10.1038/s41598-017-05938-1,.*does not cross the blood.brain barrier.*,"21, 22 showed that treatment with anti-TNFα, which does not cross the blood-brain barrier, acting only peripherally, prevents the induction of inflammation, neuroinflammation and cognitive and motor alterations in rats with MHE due to portacaval anastomosis",Fail,-,,
https://doi.org/10.1038/aps.2014.1,.*does not cross the blood.brain barrier.*, Glu also does not cross the blood brain barrier and hence is not delivered to the CNS through the ingestion of food,Pass,C(CC(=O)O)[C@@H](C(=O)O)N,Glu,0
https://doi.org/10.1038/aps.2013.20,.*does not penetrate the blood.brain barrier.*," The longer galanin 1–16 peptide has greater stability (half-life: 2–5 min in the circulation) and was employed in some studies, but it does not penetrate the blood-brain barrier (BBB)38",Pass,-,galanin 1–16 peptide,0
https://doi.org/10.1186/s13024-017-0154-3,.*does not cross the blood.brain barrier.*," As results from the enzyme-replacement therapies in GD show that GCase does not cross the blood-brain barrier (BBB), the development of small-molecule chaperones to correct the folding of GCase - thereby enhancing GCase activity and lysosomal function - is currently a topic of great interest [148]",Pass,-,GCase,0
https://doi.org/10.1186/s12943-017-0679-7,.*unable to cross the blood.brain barrier.*," Although it is likely playing a critical role in the brain, tumour targeted delivery or the use of inhibitors that are unable to cross the blood-brain barrier may present as viable future therapeutic options",Fail,-,,
https://doi.org/10.1186/s13023-017-0670-9,.*inability to cross the blood.brain barrier.*," However, ERTs generally have shortcomings such as inconvenient intravenous administration, inability to cross the blood-brain barrier, and high cost",Fail,-,,
https://doi.org/10.1186/s13023-017-0662-9,.*unable to cross the blood.brain barrier.*, It is not recommended for the severe Hurler form because the enzyme is unable to cross the blood-brain barrier,Fail,-,,
https://doi.org/10.1186/s13023-017-0662-9,.*inability to cross the blood.brain barrier.*," ERT may also significantly improve pre-transplant clinical conditions despite its inability to cross the blood-brain barrier and therefore absent/limited beneficial effect on cognitive functions [6, 45]",Fail,-,,
https://doi.org/10.1186/s40734-017-0054-2,.*does not cross the blood.brain barrier.*," ERT is based on the intravenous administration of recombinant GCase, which does not cross the blood-brain barrier [11]",Fail,-,,
https://doi.org/10.1038/npp.2016.103,.*does not cross the blood.brain barrier.*," However, it must be noted that GABA does not cross the blood brain barrier",Duplicate,C(CC(=O)O)CN,GABA,0
https://doi.org/10.1007/s12035-014-8726-5,.*does not cross the blood.brain barrier.*," In general, GABA does not cross the blood-brain barrier [129]",Duplicate,C(CC(=O)O)CN,GABA,0
https://doi.org/10.1007/s00213-017-4593-x,.*does not cross the blood.brain barrier.*," Thus, rats will self-administer cocaine methiodide, a quaternary derivative of cocaine that does not cross the blood brain barrier, only if they have had previous experience of self-administering cocaine (Wang et al",Duplicate,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-], cocaine methiodide,0
https://doi.org/10.1038/sj.npp.1301023,.*does not cross the blood.brain barrier.*, Any effect of Gd-DTPA on the data sampled from the selected brain volume is expected to be negligible because Gd-DTPA does not cross the blood–brain barrier under normal conditions,Pass,-,Gd-DTPA,0
https://doi.org/10.1038/oncsis.2017.33,.*does not cross the blood.brain barrier.*," We also discover that THZ1, in its current format, does not cross the blood–brain barrier and hence will require reformatting for use as an HGG therapeutic",Duplicate,CN(C)C/C=C/C(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl,THZ1,0
https://doi.org/10.1038/srep46461,.*does not cross the blood.brain barrier.*," There is increasing evidence that endogenous apolipoprotein E(apoE) modifies the neuroinflammatory response through its role in downregulating glial activation, however, the intact apoE holoprotein does not cross the blood-brain barrier due to its size",Fail,-,,
https://doi.org/10.1038/s41598-018-35716-6,.*does not cross the blood.brain barrier.*," We also provide evidence that GDF11 does not cross the blood brain barrier (BBB) and that the endothelial cells of the cerebral vasculature are responsive to GDF11, suggesting that GDF11 exerts at least a portion of its CNS effects through the vasculature",Pass,-,GDF11,0
https://doi.org/10.1038/pr.2017.243,.*does not cross the blood.brain barrier.*," For example, in contrast to EPO and BDNF, GDNF does not cross the blood–brain barrier, which makes exogenous administration of GDNF more difficult (61)",Pass,-,GDNF,0
https://doi.org/10.1007/s11940-017-0449-2,.*unable to cross the blood.brain barrier.*,"It has been of dispute whether immune checkpoint inhibitors can reveal their full therapeutic potential in BM, as these monoclonal antibodies with a large molecular weight are unable to cross the blood brain barrier [8, 9]",Fail,-,,
https://doi.org/10.1186/1471-230X-5-5,.*does not cross the blood.brain barrier.*, With regard to the characteristic physiological feature that peripheral ghrelin does not cross the blood-brain barrier in rodents it is important to note that the arcuate nucleus is the only hypothalamic structure located outside the brain-blood barrier [30],Pass,-,ghrelin,0
https://doi.org/10.1186/s12974-017-0804-y,.*does not cross the blood.brain barrier.*, This compound does not cross the blood brain barrier [30] so that centrally mediated effects can be excluded,Fail,-,,
https://doi.org/10.1038/srep41382,.*does not cross the blood.brain barrier.*," Although peripheral glutamate does not cross the blood-brain barrier (BBB) under normal conditions18, pathological conditions may increase BBB permeability and allow for bidirectional glutamate transport",Fail,-,,
https://doi.org/10.1186/s13195-016-0231-9,.*does not cross the blood.brain barrier.*,Exactly how the relative ratio of apoE4 over apoE3 isoform levels in plasma can be related to the described structural and metabolic differences in the brain is not clear and linking peripheral apoE levels to processes in the brain is controversial because peripheral apoE does not cross the blood–brain barrier (BBB) [48],Fail,-,,
https://doi.org/10.1007/s11064-015-1675-1,.*does not cross the blood.brain barrier.*," Under normal circumstances, glutamate does not cross the blood–brain barrier [45]",Pass,C(CC(=O)[O-])C(C(=O)[O-])[NH3+],glutamate,0
https://doi.org/10.1007/s11095-009-9939-6,.*does not cross the blood.brain barrier.*," However, GDNF does not cross the blood-brain barrier (BBB)",Duplicate,-,GDNF,0
https://doi.org/10.1007/s11095-008-9815-9,.*does not cross the blood.brain barrier.*," However, GDNF does not cross the blood–brain barrier (BBB) (4,5)",Duplicate,-,GDNF,0
https://doi.org/10.1007/s13311-020-00897-4,.*does not cross the blood.brain barrier.*," The anticholinergic glycopyrrolate circumnavigates the risk of cognitive impairment because it does not cross the blood–brain barrier, but it still can produce peripherally mediated adverse effects such as urinary retention and constipation",Pass,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,0
https://doi.org/10.1186/s13063-020-4089-6,.*inability to cross the blood.brain barrier.*," Glycopyrronium bromide was selected as placebo for this trial given it has similar antimuscarinic properties to scopolamine hydrobromide but an inability to cross the blood–brain barrier, thereby hypothetically mimicking only the peripheral effects of scopolamine",Pass,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C,Glycopyrronium bromide,0
https://doi.org/10.1038/npp.2016.134,.*does not cross the blood.brain barrier.*," The aromatic L-amino acid decarboxylase (AADC) inhibitor benserazide, which does not cross the blood–brain barrier, was used to prevent the 5-HT syndrome induced by 5-HTP peripheral metabolism (Hedge et al, 1994)",Fail,-,,
https://doi.org/10.1038/srep38305,.*does not cross the blood.brain barrier.*," Currently, exogenous enzyme replacement using recombinant alpha-L-iduronidase is available to patients with MPS-I, although it does not cross the blood brain barrier in significant amounts2",Fail,-,,
https://doi.org/10.1038/nmicrobiol.2016.226,.*inability to cross the blood.brain barrier.*," While these lethal models have value for vaccine and immunotherapeutic testing29, small-molecule inhibitors that are effective in the lung may be limited in their efficacy due to an inability to cross the blood–brain barrier30",Fail,-,,
https://doi.org/10.1186/s12958-018-0400-8,.*does not cross the blood.brain barrier.*," For this purpose, we used guanethidine monosulfate (GTD) as a pharmacological tool that destroys only peripheral noradrenergic fibers [27], as GTD does not cross the blood-brain barrier [28]",Pass,C1CCCN(CCC1)CCN=C(N)N.OS(=O)(=O)O,guanethidine monosulfate,0
https://doi.org/10.1038/sj.npp.1300586,.*does not cross the blood.brain barrier.*," Hexamethonium, which does not cross the blood–brain barrier, was tested at a dose that was higher than the highest ineffective dose (3 mg/kg/s",Pass,C[N+](C)(C)CCCCCC[N+](C)(C)C,Hexamethonium,0
https://doi.org/10.1038/labinvest.2016.98,.*does not cross the blood.brain barrier.*," Because dopamine does not cross the blood–brain barrier, they hypothesized involvement of the sympathetic nervous system",Duplicate,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1038/pr.2016.117,.*does not cross the blood.brain barrier.*, These findings suggest that there may exist a “compartmentalization” of cytokine responses whereas cytokines produced in response to noncentral nervous system infection which does not cross the blood-brain barrier,Fail,-,,
https://doi.org/10.1038/tp.2016.200,.*unable to cross the blood.brain barrier.*," Although surprising, this peripheral QA is unable to cross the blood–brain barrier and therefore has no direct impact on central QA concentrations and does not contribute to the behavioral phenotype of HAAO−/− mice",Fail,-,,
https://doi.org/10.1186/s12974-016-0710-8,.*does not cross the blood.brain barrier.*," Due to its large size, anti-TNF-α does not cross the blood–brain barrier, suggesting that its beneficial effects are a consequence of reduced peripheral inflammation",Fail,-,,
https://doi.org/10.1186/s13063-020-4089-6,.*does not cross the blood.brain barrier.*," As such, the present study will use glycopyrrolate as the active placebo as it is a muscarinic antagonist that does not cross the blood–brain barrier and should consequently mimic the peripheral muscarinic effects of scopolamine leading to superior blinding to saline (as previously used) [5–9]",Duplicate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,0
https://doi.org/10.1038/srep30745,.*does not cross the blood.brain barrier.*," As a quaternary ammonium derivative, this drug does not appear to affect the CNS because it does not cross the blood-brain barrier (BBB)34",Fail,-,,
https://doi.org/10.1007/s10585-016-9796-8,.*does not cross the blood.brain barrier.*," This has been shown in breast cancer patients who relapsed with brain metastases that were being treated with an antibody that does not cross the blood–brain barrier [68], or in pancreatic ductal adenocarcinoma where drug penetration is poor due to an extensive stromal envelope [69]",Fail,-,,
https://doi.org/10.1038/srep30275,.*unable to cross the blood.brain barrier.*," To recognize the IP substrate the catalytic cavity is a highly polar pocket which favors polar charged compounds, typically unable to cross the blood-brain barrier (BBB)19",Fail,-,,
https://doi.org/10.1007/s41981-018-0015-4,.*does not pass through the blood.brain barrier.*, Glycopyrrolate displays few side effects because it does not pass through the blood brain barrier,Duplicate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],Glycopyrrolate,0
https://doi.org/10.1007/s12630-017-0920-2,.*does not cross the blood.brain barrier.*," Importantly, glycopyrrolate does not cross the blood brain barrier and therefore does not cause CNS anticholinergic toxicity as with atropine",Duplicate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,0
https://doi.org/10.1038/leu.2016.57,.*inability to cross the blood.brain barrier.*, Another potential limitation common for therapeutic antibodies is their inability to cross the blood–brain barrier,Fail,-,,
https://doi.org/10.1007/s12630-013-0064-y,.*does not cross the blood.brain barrier.*,"15 In contrast to atropine, a tertiary amine, glycopyrrolate does not cross the blood-brain barrier and cannot affect the central nervous system",Duplicate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,0
https://doi.org/10.1007/s12630-013-9932-8,.*does not cross the blood.brain barrier.*, Glycopyrrolate (1/4th to 1/5th the dose of neostigmine) is preferred because it does not cross the blood brain barrier and its time course of action matches that of neostigmine better than atropine,Duplicate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],Glycopyrrolate,0
https://doi.org/10.1007/BF03008533,.*does not penetrate the blood.brain barrier.*," Although both glycopyrrolate and atropine inhibit PChE to the same extent, glycopyrrolate should be utilized in patients in whom inhibition of brain PChE or central effects ought to be avoided, since glycopyrrolate does not penetrate the blood-brain barrier",Duplicate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,0
https://doi.org/10.1038/srep25309,.*unable to pass through the blood.brain barrier.*," However, most therapeutic drugs demonstrate only modest or no therapeutic benefits because these drugs are unable to pass through the blood brain barrier (BBB)4",Fail,-,,
https://doi.org/10.1186/s10194-019-0984-1,.*unable to cross the blood.brain barrier.*," Because histamine is unable to cross the blood-brain barrier and H1 receptors are present in the endothelium of cerebral arteries, migraine attacks could have an origin in the walls of intracerebral arteries and not in the brain itself [41]",Pass,C1=C(NC=N1)CCN,histamine,0
https://doi.org/10.1007/s00520-015-3020-2,.*unable to cross the blood.brain barrier.*," However, chemotherapeutic agents are generally unable to cross the blood brain barrier and therefore should theoretically be unable to damage central neurons, strongly implying chemotherapy induces pain via other mechanisms",Fail,-,,
https://doi.org/10.1186/s13023-016-0437-8,.*does not cross the blood.brain barrier.*," Enzyme replacement therapy with laronidase (recombinant human α-L-iduronidase, Aldurazyme®) targets non-neurological manifestations as the recombinant enzyme does not cross the blood-brain barrier",Fail,-,,
https://doi.org/10.1186/1471-2407-11-124,.*does not cross the blood.brain barrier.*," This staining pattern has been described elsewhere [26, 27] and is consistent with the fact that Hoechst 33342 does not cross the blood-brain barrier",Pass,CCOC1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)C4=NC5=C(N4)C=C(C=C5)N6CCN(CC6)C,Hoechst 33342,0
https://doi.org/10.1038/srep23723,.*does not cross the blood.brain barrier.*,"It has been shown that NAA does not cross the blood brain barrier from the peripheral blood stream to the brain31,32",Duplicate,C1=CC=C2C(=C1)C=CC=C2CC(=O)O,NAA,0
https://doi.org/10.1038/mp.2015.87,.*does not cross the blood.brain barrier.*," There is evidence from animal studies that CRP per se, which is produced in the periphery, does not cross the blood–brain barrier under ordinary circumstances; however, high levels of peripheral CRP can increase the blood–brain barrier paracellular permeability by affecting the function of tight junctions",Fail,-,,
https://doi.org/10.1186/s12885-019-6316-7,.*does not cross the blood.brain barrier.*,"Imatinib, the mainstay medical treatment for GIST, does not cross the blood-brain barrier, and as such may offer limited clinical benefit to patients with intracranial metastasis [3]",Pass,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,Imatinib,0
https://doi.org/10.1016/S0893-133X(99)00055-X,.*unable to penetrate the blood.brain barrier.*," 1998) as well as by ICV administration of hexamethonium, a nAChR-antagonist unable to penetrate the blood brain barrier (Malin et al",Duplicate,C[N+](C)(C)CCCCCC[N+](C)(C)C,hexamethonium,0
https://doi.org/10.1038/ncomms11017,.*does not cross the blood.brain barrier.*," However, leakage of tail vein-injected cadaverine-Alexa-555, a small tracer that normally does not cross the blood–brain barrier19, was reduced in the Vegfr2Y949F/Y949F gliomas compared with WT at D18, both intratumourally and in the tumour periphery (0–500 μm peritumourally; Fig",Fail,-,,
https://doi.org/10.1038/s41598-020-70290-w,.*does not cross the blood.brain barrier.*," HPβCD does not cross the blood–brain barrier (BBB)5, and HPβCD administration to NPC1 patients uses intrathecal administration via injections into the lumbar cerebrospinal fluid (CSF)6",Pass,-,HPbetaCD,0
https://doi.org/10.1038/s41598-017-14162-w,.*does not cross the blood.brain barrier.*, Histamine released from peripheral mast cells may not be able to affect sleep because peripheral histamine does not cross the blood–brain barrier,Duplicate,C1=C(NC=N1)CCN,histamine,0
https://doi.org/10.1038/s41598-017-13698-1,.*was not able to cross the blood.brain barrier.*," Interestingly, with respect to control animals, no enhance in copper content was detectable in brain, thus suggesting that HydroCuP was not able to cross the blood–brain barrier",Pass,-,HydroCuP,0
https://doi.org/10.1007/s12026-014-8513-4,.*does not cross the blood.brain barrier.*," Hypocretin does not cross the blood–brain barrier well, and although creating brain penetrating agonists for peptide receptor can be challenging, it is likely a matter of time before such compounds become available for treating daytime sleepiness and narcolepsy",Pass,-,Hypocretin,0
https://doi.org/10.1186/s13023-019-1207-1,.*does not cross the blood.brain barrier.*," The improvements in measurable neurocognitive function in some patients, as well as the unsolicited reports of increased alertness and focus in even the most severely affected patients, conflict with our prior notion that HPβCD does not cross the blood brain barrier (BBB) and would therefore not be expected to affect clinically apparent change [74]",Duplicate,-,HPbetaCD,0
https://doi.org/10.1038/pr.2015.207,.*does not cross the blood.brain barrier.*," It has sufficient potency (6), does not cross the blood–brain barrier at therapeutic doses (17), is not photochemically active (14), minimally upregulates HO-1 (15), has a rapid onset of action and is short acting (2–12 h) (18), and does not affect other enzymes (7,19)",Fail,-,,
https://doi.org/10.1007/s00125-015-3795-1,.*inability to cross the blood.brain barrier.*," Furthermore, the large molecular size of albiglutide and its likely inability to cross the blood–brain barrier may also account for the difference in GI tolerability when comparing albiglutide with other members of its class",Fail,-,,
https://doi.org/10.1038/srep21973,.*does not cross the blood.brain barrier.*," These complications relate to the fact that HPβCD does not cross the blood-brain barrier62, with the result that current treatment involves direct administration to CSF",Duplicate,-,HPbetaCD,0
https://doi.org/10.1038/gim.2015.36,.*does not penetrate the blood.brain barrier.*,) enzyme replacement therapy does not affect cognitive impairment because recombinant iduronate-2-sulfatase (idursulfase) does not penetrate the blood–brain barrier at therapeutic concentrations,Fail,-,,
https://doi.org/10.1038/gim.2015.36,.*does not penetrate the blood.brain barrier.*,"Weekly infusions of idursulfase, recombinant human I2S (Elaprase, Shire, Lexington, MA), have been shown to improve some somatic manifestations in MPS II patients,5,6 but the enzyme does not penetrate the blood–brain barrier at therapeutic doses or alter cognitive decline in severe disease",Fail,-,,
https://doi.org/10.1038/srep18218,.*does not cross the blood.brain barrier.*," Our findings have to be regarded with several major limitations in mind: (i) we did not assess whether higher or lower doses of URB694 can affect cardiac function in a dose-dependent fashion, (ii) we did not clarify whether the cardioprotective effects of URB694 are mediated by facilitation of CB1 receptor-mediated AEA signaling at the peripheral and/or central level (for instance, this could be achieved by inhibiting FAAH with an URB694-like molecule that does not cross the blood brain barrier) and (iii) we did not thoroughly investigated the effects of CB1 and CB2 receptor blockade with rimonabant and AM630, respectively, on cardiac function",Fail,-,,
https://doi.org/10.1186/1477-7827-3-10,.*does not cross the blood.brain barrier.*, This is in accordance with previous reports that ICI does not cross the blood-brain barrier [15] and hence does not alter the hormonal profile,Pass,-,ICI,0
https://doi.org/10.1007/s10545-017-0075-x,.*does not cross the blood.brain barrier.*, Intravenously delivered idursulfase does not cross the blood–brain barrier in therapeutic concentrations and would not be expected to address the cognitive aspects of disease directly (Muenzer et al 2006; Muenzer et al 2012),Pass,-,idursulfase,0
https://doi.org/10.1007/s10545-014-9686-7,.*does not cross the blood.brain barrier.*," Because idursulfase does not cross the blood–brain barrier (Boado et al 2013), these improvements are likely due to improved sleep or respiration leading to the children having greater interactions with their environments and are not due to any direct action of the drug upon the brain",Duplicate,-,idursulfase,0
https://doi.org/10.1038/srep16349,.*unable to cross the blood.brain barrier.*, It is unstable and unable to cross the blood-brain barrier14,Fail,-,,
https://doi.org/10.1038/gt.2014.96,.*does not cross the blood.brain barrier.*,"Direct delivery of recombinant IL-10, however, has been found to be impractical because IL-10 does not cross the blood–brain barrier5 and, when given IT, its half-life of elimination in the CSF is 2 h",Pass,-,IL-10,0
https://doi.org/10.1038/srep14944,.*inability to cross the blood.brain barrier.*, The toxicity of anti-prion compounds and their inability to cross the blood-brain barrier has limited their successful application18,Fail,-,,
https://doi.org/10.1007/s10237-015-0662-4,.*unable to cross the blood.brain barrier.*,"Infusion is a procedure during which fluid is injected into the brain, either to administer drugs, which cannot enter from the vasculature as they are unable to cross the blood brain barrier, or to investigate cerebral compliance of the brain",Fail,-,,
https://doi.org/10.1186/s13075-015-0784-1,.*unable to penetrate the blood.brain barrier.*," However, anti-TNF agents are unable to penetrate the blood–brain barrier [69]",Fail,-,,
https://doi.org/10.1186/s13023-017-0635-z,.*does not cross the blood.brain barrier.*," In addition, it is important to note that idursulfase does not cross the blood–brain barrier and so treatment of neurological aspects of the disease remains challenging",Duplicate,-,idursulfase,0
https://doi.org/10.1186/s12876-021-01712-w,.*does not cross the blood.brain barrier.*," Since itopride does not cross the blood brain barrier thus does not exhibit ADEs related to CNS, it also hardly increases prolactin levels and does not prolong the QT interval [16]",Pass,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC,itopride,0
https://doi.org/10.1007/s40262-015-0265-3,.*does not cross the blood.brain barrier.*," Carbidopa reduces peripheral decarboxylation of levodopa to dopamine (which does not cross the blood–brain barrier) and directs more levodopa metabolism towards the catechol-O-methyl transferase (COMT) enzyme pathway (which generates the inactive metabolite, 3-O-methyldopa)",Fail,-,,
https://doi.org/10.1186/1750-1172-6-72,.*does not pass through the blood.brain barrier.*," Unfortunately, options for alleviating the neurological manifestations of MPS II remain limited: intravenously administered idursulfase does not pass through the blood-brain barrier, and experience of intrathecal administration of ERT is restricted to small clinical trials",Duplicate,-,idursulfase,0
https://doi.org/10.1186/s40064-015-1206-1,.*does not cross the blood.brain barrier.*,"Among youngsters, domperidone should be preferred over metoclopramide (Pereira-Monteiro 2009) because it does not cross the blood–brain barrier (Teixeira 2001)",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1186/s40064-015-1206-1,.*does not cross the blood.brain barrier.*,"This case illustrates several important messages in quaternary prevention during migraine management: (1) use of acetaminophen is not based in high-quality evidence and better options exist; (2) among youngsters, domperidone should be preferred over metoclopramide because it does not cross the blood–brain barrier; (3) moderate to severe migraine crisis can be managed with triptans in teenagers over 12 years old; (4) it is important to recognize adverse drug effects; (5) harmful consequences of medical interventions do occur; (6) the school community must be informed about chronic diseases of the young",Duplicate,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,domperidone,0
https://doi.org/10.1186/s12974-020-01746-z,.*does not cross the blood.brain barrier.*," Infliximab is an anti-TNF-a antibody that does not cross the blood-brain barrier [40], binds to peripheral TNF-a, and reduces peripheral inflammation in rats with MHE or hyperammonemia [9, 10, 22]",Pass,-,Infliximab,0
https://doi.org/10.1007/s15010-014-0611-7,.*does not penetrate the blood.brain barrier.*, Itraconazole does not penetrate the blood–brain barrier,Pass,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,Itraconazole,0
https://doi.org/10.1007/s13311-017-0538-7,.*does not cross the blood.brain barrier.*," Since ivabradine does not cross the blood–brain barrier, a brain-permeable derivative will be necessary for therapeutic action within the central nervous system [200]",Pass,CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC,ivabradine,0
https://doi.org/10.1186/s12883-019-1267-9,.*unable to cross the blood.brain barrier.*," In contrast to KYN, KYNA is unable to cross the blood brain barrier (BBB)",Pass,C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O,KYNA,0
https://doi.org/10.1038/srep21887,.*unable to cross the blood.brain barrier.*," depression, by increasing muscle kynurenine conversion into kynurenic acid that is unable to cross the blood brain barrier10",Pass,C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O,kynurenic acid,0
https://doi.org/10.1186/s40199-015-0120-y,.*does not cross the blood.brain barrier.*," Although lapatinib does not cross the blood–brain barrier, it can reach therapeutic levels in brain tumours and brain metastases [7]",Pass,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,lapatinib,0
https://doi.org/10.1038/mp.2015.28,.*does not cross the blood.brain barrier.*,"53 However, the HCN1 antagonist ivabradine, approved in Europe for angina, does not cross the blood–brain barrier",Duplicate,CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC,ivabradine,0
https://doi.org/10.1007/s40264-015-0296-6,.*unable to cross the blood.brain barrier.*, PCSK9 inhibitors are antibodies which generally are unable to cross the blood-brain barrier without engineered “shuttle” molecules [22],Fail,-,,
https://doi.org/10.1186/s12891-020-03478-w,.*unable to cross the blood.brain barrier.*,"Activation of skeletal muscle increases secretion of peroxisome proliferator-activated receptor-gamma co-activator-1 alpha 1 [32], which promotes skeletal muscle expression of kynurenine aminotransferase, thereby facilitating transformation of kynurenine into kynurenic acid [33], a metabolism product unable to cross the blood-brain barrier [34]",Duplicate,C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O,kynurenic acid,0
https://doi.org/10.1038/ijo.2015.28,.*inability to cross the blood.brain barrier.*," Nevertheless, because these peptides normally regulate food intake directly in the hypothalamus, their anorexigenic potential after peripheral administration is hampered by their inability to cross the blood-brain barrier (BBB) and to reach the target brain receptors",Fail,-,,
https://doi.org/10.1186/s12933-018-0702-3,.*does not cross the blood.brain barrier.*, We did not detect linagliptin under our experimental conditions in agreement with previous published data demonstrating that linagliptin does not cross the blood brain barrier under physiological conditions [55],Pass,CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C,linagliptin,0
https://doi.org/10.1007/s11832-015-0661-0,.*unable to cross the blood.brain barrier.*, Enzymes are unable to cross the blood–brain barrier so provide no cognitive benefit in severe MPS I,Fail,-,,
https://doi.org/10.1186/s13023-019-1027-3,.*does not cross the blood.brain barrier.*," However, since IV laronidase does not cross the blood-brain barrier, it does not treat the CNS manifestations of MPS I, and thus patients may experience neurocognitive deficits throughout life",Pass,-,laronidase,0
https://doi.org/10.1007/s40800-018-0077-0,.*does not cross the blood.brain barrier.*," At therapeutic doses loperamide does not cross the blood–brain barrier and thus typically does not cause central nervous system effects, including the euphoric effect associated with centrally acting opiates",Pass,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,loperamide,0
https://doi.org/10.1007/s40262-017-0612-7,.*does not penetrate the blood.brain barrier.*,"04) that inhibits SERT; however, based on nonclinical data, Lu AA39835 does not penetrate the blood–brain barrier (data on file)",Pass,CC1=CC(=C(C=C1)SC2=C(C=CC(=C2)O)N3CCNCC3)C,Lu AA39835,0
https://doi.org/10.1007/s40674-014-0005-0,.*does not cross the blood.brain barrier.*," It is comparable in efficacy to metoclopramide, but the CNS side effects are reduced, as it does not cross the blood-brain barrier",Fail,-,,
https://doi.org/10.1007/s40263-014-0221-z,.*does not cross the blood.brain barrier.*," This potent D2 antagonist does not cross the blood brain barrier, so can reduce peripheral side effects of apomorphine, especially nausea, without mitigating the desired CNS effect",Fail,-,,
https://doi.org/10.1038/gim.2016.223,.*does not penetrate the blood.brain barrier.*," However, because laronidase does not penetrate the blood–brain barrier, hematopoietic cell transplantation (HCT) is recommended for MPS IH in addition to ERT",Duplicate,-,laronidase,0
https://doi.org/10.1186/s13023-015-0344-4,.*does not cross the blood.brain barrier.*," In our case series, both siblings in sibship 4 had a reported ERT compliance rate of 60 %, and the younger sibling experienced progressive joint contractures and cognitive delays similar to the older sibling despite initiating therapy at an earlier age While cognitive function is not believed to be directly affected by ERT in patients with MPS I since laronidase does not cross the blood brain barrier, improvements in somatic disease following ERT may impact results of cognitive testing",Duplicate,-,laronidase,0
https://doi.org/10.1186/1750-1172-7-22,.*does not cross the blood.brain barrier.*," Because intravenously administered laronidase does not cross the blood-brain barrier [18], ERT cannot prevent cognitive decline in patients with MPS I-H",Duplicate,-,laronidase,0
https://doi.org/10.1186/1750-1172-6-55,.*unable to cross the blood.brain barrier.*," Laronidase is unable to cross the blood brain barrier in significant quantity, at least in the recommended dose (100 IU/kg/week) [13], and will therefore not prevent cognitive decline in patients with MPS I-H",Duplicate,-,Laronidase,0
https://doi.org/10.1186/s12974-018-1328-9,.*does not cross the blood.brain barrier.*," Although LPS does not cross the blood-brain barrier at significant levels [20], it could be interacting with juxta-cerebrovascular cells to transmit an immune signal across the barrier",Pass,-,LPS,0
https://doi.org/10.1038/bjc.2014.388,.*inability to cross the blood.brain barrier.*,The incidence of BM in patients with HER2+ MBC increases over time and may be attributable partly to marked reduction in mortality as a result of HER2 inhibition and control of non-CNS metastatic progression and monoclonal antibodies’ inability to cross the blood brain barrier (BBB),Fail,-,,
https://doi.org/10.1038/boneres.2014.34,.*does not cross the blood.brain barrier.*,267 These results suggest that an orally active inhibitor of gut TPH1 that does not cross the blood–brain barrier might be a novel anabolic agent for treating osteoporosis,Fail,-,,
https://doi.org/10.1186/1743-7075-3-15,.*unable to cross the blood.brain barrier.*,"In order for malonyl CoA to function as a regulator of appetite-control feeding behaviours, the presence of the ACC isoform and its regulation in brain is mandatory since malonyl CoA produced in the liver is unable to cross the blood brain barrier",Pass,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSC(=O)CC(=O)O)O,malonyl CoA,0
https://doi.org/10.1038/ijo.2014.14,.*does not cross the blood.brain barrier.*,"As the majority of 5HT body’s pool (95%) is produced by enterochromaffin (EC) cell within the gut (mainly in the antrum and duodenum), and because the gut-derived 5HT does not cross the blood–brain barrier and was suggested to be a multifunctional adapter to starvation,28 we determined whether a gastric leptin—5HT pathway may exist",Fail,-,,
https://doi.org/10.1038/nrdp.2016.14,.*does not cross the blood.brain barrier.*," As loperamide does not cross the blood–brain barrier, central adverse effects are limited",Duplicate,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,loperamide,0
https://doi.org/10.1007/s10545-014-9686-7,.*does not cross the blood.brain barrier.*," This likely reflects an increased ability of these patients to interact with others and with their environment due to improved mobility, improved sleep, and/or reductions in respiratory disease burden, since idursulfase does not cross the blood–brain barrier (Boado et al 2013)",Duplicate,-,idursulfase,0
https://doi.org/10.1186/1475-2891-13-80,.*unable to cross the blood.brain barrier.*,"However, since central dopamine is unable to cross the blood–brain barrier [25], it is challenging to appropriately measure its activity",Duplicate,C1=CC(=C(C=C1CCN)O)O,dopamine,0
https://doi.org/10.1007/s10620-015-3615-y,.*does not cross the blood.brain barrier.*, Loperamide does not cross the blood–brain barrier and does not have these adverse effects,Duplicate,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,Loperamide,0
https://doi.org/10.1186/1745-6673-2-16,.*does not cross the blood.brain barrier.*," Loperamide, which does not cross the blood-brain barrier but exerts antinociceptive effects after direct injection into the brain, was loaded into human serum albumin nanoparticles and linked to apolipoprotein E",Duplicate,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,Loperamide,0
https://doi.org/10.1186/1471-2407-14-543,.*unable to cross the blood.brain barrier.*, These data probably reflect the impossibility to reach a high cerebrospinal fluid drug concentration with the actual cytotoxic agents most active in EOC which are unable to cross the blood–brain barrier,Fail,-,,
https://doi.org/10.1007/s00125-005-1791-6,.*does not cross the blood.brain barrier.*,"After the activation of opioid μ-receptors, tramadol is an effective treatment to handle the pain in clinic with some non-opioid effects [15], while loperamide is a peripheral agonist that does not cross the blood–brain barrier and lacks the side-effects produced by centrally acting opiates [16]",Duplicate,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,loperamide,0
https://doi.org/10.1203/PDR.0b013e31815b4421,.*does not cross the blood.brain barrier.*," Additionally, bicuculline methiodide (which does not cross the blood brain barrier) was given during hypoxia and did not have an effect on ventilation",Pass,CI,methiodide,0
https://doi.org/10.1007/s40142-014-0038-6,.*inability to cross the blood.brain barrier.*," If performed early enough in the disease course, this has the potential to impact central nervous system disease, a key system otherwise unreachable by peripheral enzyme replacement therapy because of its inability to cross the blood-brain barrier [10]",Fail,-,,
https://doi.org/10.1038/srep25457,.*does not cross the blood.brain barrier.*," However, LPS does not cross the blood–brain barrier (BBB)6",Duplicate,-,LPS,0
https://doi.org/10.1038/ncomms5486,.*does not cross the blood.brain barrier.*," Since LPS does not cross the blood–brain barrier36, its mode of action in our model is via the activation of TLR4 on the luminal surface of brain blood vessels",Duplicate,-,LPS,0
https://doi.org/10.1186/s12904-019-0416-7,.*does not cross the blood.brain barrier.*," As an alternative methylnaltrexone, a quaternary amine of naltrexone that does not cross the blood-brain barrier, can be prescribed",Pass,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,methylnaltrexone,0
https://doi.org/10.1007/s12094-013-1110-5,.*unable to cross the blood.brain barrier.*," Moreover, the brain may represent a preferential site of metastasis as many of the currently available therapies are unable to cross the blood–brain barrier (BBB), even if this barrier is disrupted by tumor invasion",Fail,-,,
https://doi.org/10.1038/sj.npp.1301585,.*does not cross the blood.brain barrier.*," Although the systemic administration of scopolamine did not allow regional localization of this effect, the absence of an effect by methylscopolamine (which does not cross the blood–brain barrier) demonstrated central mechanisms (Chen et al, 2004)",Pass,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,methylscopolamine,0
https://doi.org/10.1186/1744-8069-8-54,.*does not cross the blood.brain barrier.*," As mibefradil does not cross the blood–brain barrier, this antihyperalgesic effect is thought to be largely localized to the primary afferent neuron [4–6]",Pass,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,mibefradil,0
https://doi.org/10.1007/s40124-013-0033-5,.*inability to penetrate the blood.brain barrier.*,"Other than age-related biological diversity, another explanation for the lack of current pharmacotherapy in pediatric HGGs reflects an inability to penetrate the blood-brain barrier, with chemotherapy efflux occurring secondary to inherent drug transporter molecules, thereby conferring apparent resistance [75, 76]",Fail,-,,
https://doi.org/10.1007/s10286-017-0434-6,.*does not cross the blood.brain barrier.*," Note that midodrine does not cross the blood-brain barrier, and its use, as with fludrocortisone and droxidopa, is associated with supine hypertension",Pass,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,midodrine,0
https://doi.org/10.1038/mi.2013.52,.*does not cross the blood.brain barrier.*," Pretreatment with atropine methyl nitrate (AMN), an mAChR antagonist that does not cross the blood–brain barrier, failed to alter the beneficial effects of GAL on colitis (Figure 3)",Duplicate,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[N+](=O)([O-])[O-],atropine methyl nitrate,0
https://doi.org/10.1016/S0893-133X(99)00083-4,.*does not cross the blood.brain barrier.*,"In order to determine if the effects of scopolamine observed in Experiment 1 were due to action in the central nervous system, we examined the effect of pre-training methylscopolamine, which does not cross the blood-brain barrier but remains active peripherally (Brown 1993)",Duplicate,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,methylscopolamine,0
https://doi.org/10.1038/ncomms10068,.*does not cross the blood.brain barrier.*," Nevertheless, although MMC is used in the clinic for other cancers, it does not cross the blood–brain barrier and has not been used for GBM",Pass,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,MMC,0
https://doi.org/10.1186/1742-2094-11-11,.*does not cross the blood.brain barrier.*," MIF does not cross the blood brain barrier [87, 88], and differential expression in the two areas may explain the differing observations",Pass,-,MIF,0
https://doi.org/10.1007/s12630-013-0064-y,.*does not cross the blood.brain barrier.*,"23 As glycopyrrolate does not cross the blood-brain barrier,16 it might not affect the cholinergic pathways at the central nervous system",Duplicate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,0
https://doi.org/10.1038/hr.2009.115,.*does not cross the blood.brain barrier.*,"Midodrine does not cross the blood–brain barrier and, therefore, does not directly influence central nervous control of the cardiovascular system",Duplicate,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,Midodrine,0
https://doi.org/10.1038/cddis.2013.430,.*does not cross the blood.brain barrier.*,"2 The current therapeutic strategy, enzyme replacement therapy (ERT),3, 4, 5 is effective in peripheral organs but cannot treat brain deterioration because the recombinant enzyme does not cross the blood–brain barrier",Fail,-,,
https://doi.org/10.1038/s41420-020-0237-8,.*does not cross the blood.brain barrier.*,"MLN4924 does not cross the blood brain barrier, but IVT chemotherapy is now standard-of-care in several centers29",Pass,-,MLN4924,0
https://doi.org/10.1186/2051-5960-1-66,.*inability to cross the blood.brain barrier.*," R-spondin proteins hold limited potential as imaging or therapeutic agents in medulloblastoma due to their large size (35 kDa) [46] and likely inability to cross the blood–brain barrier [47, 48]",Fail,-,,
https://doi.org/10.1038/srep23723,.*does not cross the blood.brain barrier.*," Studies with rats exhibited that dietary-supplemented NAA is bioavailable30, but neither evokes systemic toxicity nor adverse effects on the CNS30,31 as NAA does not cross the blood brain barrier30,32",Pass,C1=CC=C2C(=C1)C=CC=C2CC(=O)O,NAA,0
https://doi.org/10.1186/2040-2384-2-5,.*does not cross the blood.brain barrier.*," Because MNTX does not cross the blood-brain barrier, it could play a therapeutic role in reversing the peripheral effects of opiates in palliative care, especially for patients taking high doses of opiates for analgesia [32–37]",Pass,-,MNTX,0
https://doi.org/10.1038/npp.2013.75,.*does not cross the blood.brain barrier.*,"In this study, we used cocaine methiodide (MI), a cocaine analog that does not cross the blood–brain barrier (Wise et al, 2008), to differentiate the peripheral and central effects of cocaine in animals trained to self-administer intravenous cocaine HCl (the addictive form) by lever-pressing",Duplicate,C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC)C.[I-],cocaine methiodide,0
https://doi.org/10.1038/npp.2015.248,.*does not cross the blood.brain barrier.*," We tested this hypothesis using the acquisition of a new instrumental seeking response for conditioned reinforcement (ANR), and by comparing the effects of administering at reactivation the lipophilic β-adrenergic receptor antagonist propranolol vs the hydrophilic (lipophobic) β-adrenergic receptor antagonist nadolol, which does not cross the blood–brain barrier",Pass,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,nadolol,0
https://doi.org/10.1038/sj.npp.1300163,.*does not cross the blood.brain barrier.*," To evaluate the possibility that peripheral effects of PRO could be a factor in water maze performance nadolol (NAD; a hydrophilic β-adrenergic antagonist that does not cross the blood–brain barrier effectively, Schiff and Saxey, 1984) was administered to certain groups (see Table 1)",Pass,-,NAD,0
https://doi.org/10.1007/s12325-021-01766-y,.*does not cross the blood.brain barrier.*," Naldemedine, which is structurally similar to naltrexone but does not cross the blood–brain barrier, has been investigated in phase IIb and III trials in patients with cancer and OIC [60]",Pass,CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O,Naldemedine,0
https://doi.org/10.1007/s12325-021-01766-y,.*does not cross the blood.brain barrier.*,"Naloxegol, the first orally administered PAMORA approved for the treatment of OIC, is a pegylated form of naloxone that does not cross the blood–brain barrier [60, 151] and is thus preferentially active at opioid receptors in the GI tract [151]",Pass,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O,Naloxegol,0
https://doi.org/10.1186/2047-9158-2-13,.*unable to cross the blood.brain barrier.*,"Finally, as ASCs are large cells, unable to cross the blood–brain barrier [44], intracerebral application seems to be superior to intravasal application, as only 1-2% of thus applied cells will reach the central nervous system [52]",Fail,-,,
https://doi.org/10.1186/2008-2231-21-35,.*does not pass through the blood.brain barrier.*," It does not pass through the blood–brain barrier sufficiently, so that is not able to treat CNS infection[8–11]",Fail,-,,
https://doi.org/10.1038/npp.2010.231,.*does not cross the blood.brain barrier.*," To verify the ability of ISO infusion in the PMd to induce OFC through downstream adrenergic activation at peripheral β-adrenoceptors, the rats received saline (n=7) or nadolol 10 mg/kg (n=8)—a β-blocker that does not cross the blood–brain barrier (Cruickshank et al, 1980)—intraperitoneally before ISO 40 nmol conditioning",Duplicate,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,nadolol,0
https://doi.org/10.1007/s11682-010-9098-8,.*does not pass through the blood.brain barrier.*," Nadolol does not pass through the blood-brain barrier while propranolol does, and therefore nadolol has the same peripheral effects without any of the central effects of propranolol",Duplicate,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,Nadolol,0
https://doi.org/10.1007/s40263-013-0054-1,.*unable to cross the blood.brain barrier.*," However, if the dopaminergic medication is unable to cross the blood-brain barrier this risk is very low",Fail,-,,
https://doi.org/10.1007/s40263-013-0054-1,.*does not cross the blood.brain barrier.*," However, over 90 % of administered levodopa is decarboxylated outside the CNS, and this dopamine does not cross the blood–brain barrier",Fail,-,,
https://doi.org/10.1186/1741-7015-11-81,.*unable to pass through the blood.brain barrier.*," For β-secretase (BACE), in addition to having dozens of other substrates, the active site is so large that only compounds with more than 500 molecular weight may efficiently inhibit the enzyme, but then they are unable to pass through the blood-brain barrier (BBB) [17]",Fail,-,,
https://doi.org/10.1007/s00213-007-1015-5,.*does not cross the blood.brain barrier.*," In a third experiment, we tested for the contribution of peripheral β-blockade to the attentional effects seen with propranolol by administering nadolol, a β-blocker that does not cross the blood–brain barrier (BBB)",Duplicate,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,nadolol,0
https://doi.org/10.1038/s41536-021-00175-7,.*does not cross the blood.brain barrier.*," NalM is a non-selective and competitive antagonist of µ- (MOR), δ- (DOR) and κ- (KOR) opioid receptors that is restricted to peripheral tissues as it does not cross the blood–brain barrier",Pass,-,NalM,0
https://doi.org/10.1038/s41598-018-29594-1,.*does not cross the blood.brain barrier.*," The use of naloxone methiodide, which does not cross the blood-brain barrier, and the lack of any effect of opioid treatment on feeding behaviour allow us to exclude involvement of opioid receptors located within the central nervous system and capable of affecting fat pad regeneration through control of food intake and/or energy balance",Pass,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC=C.[I-],naloxone methiodide,0
https://doi.org/10.1186/s10194-019-0984-1,.*does not cross the blood.brain barrier.*," Furthermore, Nα-methylhistamine does not cross the blood brain barrier",Pass,CNCCC1=CN=CN1,Nalpha-methylhistamine,0
https://doi.org/10.1186/s41043-015-0032-y,.*unable to cross the blood.brain barrier.*," In rats, by using an opioid antagonist unable to cross the blood-brain barrier (naloxone methobromide), intracerebroventricular (ICV)-injected gluten exorphins stimulated prolactin release through activation of opioid receptors probably also outside the brain",Pass,-,naloxone methobromide,0
https://doi.org/10.1038/bjc.2012.440,.*inability to cross the blood.brain barrier.*," It is interesting to note that prior trastuzumab-based therapy did not correlate with BO metastatic behaviour, although trastuzumab is thought to favour the development of BM owing to its inability to cross the blood-brain barrier (Bendell et al, 2003; Musolino et al, 2011)",Duplicate,-,trastuzumab,0
https://doi.org/10.1186/1742-2094-9-241,.*inability to cross the blood.brain barrier.*," However, most of these compounds failed in either pre-clinical trials or human trials due to their inability to cross the blood-brain barrier or due to limited bioavailability",Fail,-,,
https://doi.org/10.1038/s41598-018-27313-4,.*does not cross the blood.brain barrier.*,"To examine the contribution of peripheral opioid receptors, we used naloxone methiodide (NLXM), an opioid receptor antagonist that does not cross the blood-brain barrier10, in the CCI model",Duplicate,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC=C.[I-],naloxone methiodide,0
https://doi.org/10.1007/s13311-012-0150-9,.*does not cross the blood.brain barrier.*," Central administration of hypocretin-1 reverses narcolepsy in animal models [84, 85], but unfortunately the hypocretin peptide does not cross the blood brain barrier, thus a centrally penetrating agonist is needed to be usable",Fail,-,,
https://doi.org/10.1186/s12974-016-0591-x,.*unable to cross the blood.brain barrier.*," The fundamental role of enkephalins in T cell-mediated analgesia was confirmed by using naloxone methiodide, an antagonist of the three classes of opioid receptors unable to cross the blood-brain barrier (Fig",Duplicate,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC=C.[I-],naloxone methiodide,0
https://doi.org/10.1186/1744-8069-8-54,.*does not cross the blood.brain barrier.*," Interestingly, Mibefradil does not cross the blood brain barrier in significant concentrations, and is thus devoid of CNS effects [4]",Duplicate,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,Mibefradil,0
https://doi.org/10.1186/1471-2148-12-112,.*does not cross the blood.brain barrier.*," The lack of affect on the level of acox1 transcripts in the brain of zebrafish fed clofibrate may be due to: (i) clofibrate does not cross the blood brain barrier, or (ii) if clofibrate does cross the blood brain barrier, the acox1 gene is not induced by clofibrate in the brain of zebrafish",Fail,-,,
https://doi.org/10.1186/1471-2369-13-47,.*unable to penetrate the blood.brain barrier.*," In accordance with these findings, it has been reported that peripheral angiotensins were unable to penetrate the blood–brain barrier (BBB) under normal physiological conditions [8]",Fail,-,,
https://doi.org/10.1186/s13195-016-0195-9,.*does not cross the blood.brain barrier.*," However, NGF does not cross the blood-brain barrier, owing to its chemical properties, and requires targeted delivery to the brain to have a biological effect",Pass,C([C@@H]([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)NC(=O)CO)O)C(=O)C(=O)O,NGF,0
https://doi.org/10.1038/s41598-018-20210-w,.*inability to cross the blood.brain barrier.*, An important barrier towards the study of the role of norepinephrine was its inability to cross the blood-brain barrier16,Pass,C1=CC(=C(C=C1[C@H](CN)O)O)O,norepinephrine,0
https://doi.org/10.1038/cddis.2012.59,.*does not cross the blood.brain barrier.*,"8, 11, 12 Because bFGF does not cross the blood–brain barrier, we used intravenous bFGF as a pharmacological approach to determine the effects of inhibition of endothelial cell apoptosis on apoptosis of neural progenitors after irradiation",Duplicate,-,bFGF,0
https://doi.org/10.1038/npp.2011.139,.*does not cross the blood.brain barrier.*," Lack of rCBV changes in animals receiving nicotine methiodide, a quaternary nicotine analog that does not cross the blood–brain barrier, supports a direct neuronal effect of nicotine rather than an action on the vasculature",Pass,-,nicotine methiodide,0
https://doi.org/10.1038/s41598-020-74346-9,.*unable to penetrate the blood.brain barrier.*," According to a Phase III trial (ENDEAR), nusinersen showed moderate therapeutic effects with delayed disease progression and ventilation timing9, but was unable to penetrate the blood–brain barrier (BBB)",Pass,CC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)OP(=S)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OC[C@@H]8[C@H]([C@H]([C@@H](O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)OCCOC,nusinersen,0
https://doi.org/10.1038/cgt.2009.1,.*unable to cross the blood.brain barrier.*," This suggests that the NT-polyplex was unable to cross the blood–brain barrier, possibly caused by the inability of NT to penetrate the blood–brain barrier",Pass,-,NT-polyplex,0
https://doi.org/10.1007/s12035-011-8219-8,.*inability to cross the blood.brain barrier.*,A major impediment for the clinical use of neurotrophic factors is their inability to cross the blood–brain barrier in therapeutic amounts,Fail,-,,
https://doi.org/10.1038/sj.npp.1300955,.*does not cross the blood.brain barrier.*," Furthermore, by reproducing the blood pressure response to nicotine with a systemic infusion of norepinephrine, a potent vasopressor that does not cross the blood–brain barrier (Tuor et al, 2002), no detectable rCBV changes were detected centrally, thus corroborating the idea that the observed rCBV response is not the predominant result of peripheral vascular changes",Duplicate,C1=CC(=C(C=C1[C@H](CN)O)O)O,norepinephrine,0
https://doi.org/10.1186/1750-1326-6-86,.*inability to cross the blood.brain barrier.*," Utilizing radiolabeled forms of these molecules, however, was not clinically feasible due to their relative inability to cross the blood-brain barrier (BBB) and their low binding affinities for Aβ aggregates",Fail,-,,
https://doi.org/10.1007/s12672-011-0090-6,.*does not cross the blood.brain barrier.*," Features of the IMC-A12 monoclonal antibody relevant to its potential as a cancer therapeutic are that it is specific for the IGF1R receptor, it may induce antibody-dependent cellular cytotoxicity, it is administered intravenously, and while it has a relatively long half-life, it does not cross the blood–brain barrier [3, 4]",Fail,-,,
https://doi.org/10.1038/srep12007,.*does not penetrate the blood.brain barrier.*," Importantly, the data presented here show that ODM-201 does not penetrate the blood-brain barrier and does not increase serum testosterone levels suggesting that it does not stimulate production of androgens via the hypothalamic-pituitary-gonadal axis",Pass,C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,ODM-201,0
https://doi.org/10.1186/s12929-015-0166-7,.*unable to cross the blood.brain barrier.*," Nevertheless, invasive injection in the SN is the major limitation of NTS-polyplex because is unable to cross the blood–brain barrier (BBB) when injected intravenously [69]",Duplicate,-,NTS-polyplex,0
https://doi.org/10.1038/mp.2014.132,.*does not cross the blood.brain barrier.*," Once released into circulation, OXT does not cross the blood–brain barrier in significant amounts, given that the epithelial tight junctions that form this barrier are generally considered impermeable to large molecules",Pass,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,OXT,0
https://doi.org/10.1007/s13311-011-0080-y,.*does not cross the blood.brain barrier.*," However, the effect is limited because the GALC protein does not cross the blood brain barrier to reach the CNS",Fail,-,,
https://doi.org/10.1007/s13311-011-0068-7,.*inability to cross the blood.brain barrier.*," This would also circumvent issues associated with classical protein delivery approaches, such as the inability to cross the blood-brain barrier, adverse side effects caused by systemic delivery, and short protein half-life",Fail,-,,
https://doi.org/10.1007/s00415-020-09847-8,.*does not cross the blood.brain barrier.*," Nusinersen, an antisense-oligonucleotide (ASO), does not cross the blood–brain barrier [9]",Duplicate,CC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)OP(=S)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OC[C@@H]8[C@H]([C@H]([C@@H](O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)OCCOC,Nusinersen,0
https://doi.org/10.1007/s12325-019-00923-8,.*does not cross the blood.brain barrier.*," However, given that nusinersen does not cross the blood-brain barrier when delivered systemically and has a median half-life of 163 days, it requires direct delivery into the central nervous system through lifetime repeated intrathecal injections [20]",Duplicate,CC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)OP(=S)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OC[C@@H]8[C@H]([C@H]([C@@H](O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)OCCOC,nusinersen,0
https://doi.org/10.1038/npp.2011.77,.*does not cross the blood.brain barrier.*," To address this, in experiment 6, we administered sotalol, a β-adrenergic receptor antagonist that does not cross the blood–brain barrier (Dahlof, 1981)",Duplicate,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,Sotalol,0
https://doi.org/10.1038/s41467-020-14845-5,.*unable to cross the blood.brain barrier.*, OT is a hydrophilic cyclic nonapeptide and is unable to cross the blood-brain barrier (BBB) in significant amounts12,Pass,-,OT,0
https://doi.org/10.1007/s40750-014-0010-4,.*does not cross the blood.brain barrier.*," From the bloodstream, oxytocin does not cross the blood–brain barrier, and so probably does not impact the brain directly",Pass,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,oxytocin,0
https://doi.org/10.1007/s00213-011-2171-1,.*does not cross the blood.brain barrier.*," One way to address this issue is to include an experimental group that is given methyl-scopolamine, a quaternary form of SCOP that has the same receptor binding characteristics but supposedly does not cross the blood–brain barrier when given at an equivalent dose (Evans 1975; Harvey et al",Fail,-,,
https://doi.org/10.1007/s12630-011-9479-5,.*does not cross the blood.brain barrier.*," Several authors have suggested that QX-314 does not cross the blood-brain barrier, or if it does, it does so extremely slowly",Fail,-,,
https://doi.org/10.1038/s41598-017-13109-5,.*does not cross the blood.brain barrier.*," Once released into peripheral circulation, OT does not cross the blood-brain barrier in significant amounts37",Duplicate,-,OT,0
https://doi.org/10.1203/PDR.0b013e318212f562,.*does not cross the blood.brain barrier.*," Peripheral OT does not cross the blood-brain barrier easily, although it is observed in human cerebrospinal fluid (CSF) just minutes after intranasal administration (11)",Duplicate,-,OT,0
https://doi.org/10.1038/sj.mp.4002015,.*does not cross the blood.brain barrier.*,"18, 19, 20, 21 One explanation for these negative results might be the limitation of peripheral administration of OT, as it does not cross the blood–brain barrier in sufficient quantities to affect CNS processes",Duplicate,-,OT,0
https://doi.org/10.1186/s13020-021-00468-5,.*does not penetrate the blood.brain barrier.*,"Paclitaxel does not penetrate the blood–brain barrier and could not accumulate in the central nervous system but will damage the peripheral nervous system, including nerve endings, peripheral nerves, and DRG",Pass,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,Paclitaxel,0
https://doi.org/10.1007/s12028-019-00749-w,.*does not cross the blood.brain barrier.*, We are aware of the fact that phenylephrine does not cross the blood–brain barrier,Pass,CNC[C@@H](C1=CC(=CC=C1)O)O,phenylephrine,0
https://doi.org/10.1186/1744-859X-10-9,.*does not cross the blood.brain barrier.*," Since serotonin does not cross the blood-brain barrier, all its activity in the brain is mediated by phenomena of synthesis, reuptake and binding to 5HTT receptors",Duplicate,C1=CC2=C(C=C1O)C(=CN2)CCN,serotonin,0
https://doi.org/10.1007/s11095-010-0291-7,.*does not penetrate the blood.brain barrier.*," The marker is a substance that does not penetrate the blood-brain barrier, e",Fail,-,,
https://doi.org/10.1007/s11095-010-0291-7,.*does not penetrate the blood.brain barrier.*," The marker is a substance that does not penetrate the blood-brain barrier, e",Fail,-,,
https://doi.org/10.1038/cddis.2014.566,.*does not cross the blood.brain barrier.*," However, unlike the case of flank tumors, PE does not cross the blood–brain barrier and as such was not suitable for in vivo testing in our orthotopic GBM model",Pass,-,PE,0
https://doi.org/10.1038/srep40136,.*does not cross the blood.brain barrier.*," The allosteric function of ADA in support of Adora signaling is unlikely to be supported by PEG-ADA, which does not cross the blood-brain barrier",Pass,-,PEG-ADA,0
https://doi.org/10.1038/bjc.2012.99,.*does not cross the blood.brain barrier.*," PM00104 is a large molecule that does not cross the blood brain barrier, which may explain the progression of a brain metastasis in this patient",Pass,CC1=CC2=C([C@@H]3[C@@H]4CC5=C(C(=C6C(=C5[C@@H](N4[C@H]([C@H](C2)N3C)O)CNC(=O)/C=C/C7=CC(=CC=C7)C(F)(F)F)OCO6)C)OC(=O)C)C(=C1OC)O,PM00104,0
https://doi.org/10.1186/1471-2334-10-324,.*inability to cross the blood.brain barrier.*," For this reason, actually this combined therapy is been questioned, moreover of the drug's associated nephrotoxicity and inability to cross the blood-brain barrier",Fail,-,,
https://doi.org/10.1007/s10792-009-9319-6,.*does not cross the blood.brain barrier.*," Since IgM antibody does not cross the blood–brain barrier, its presence in the cerebrospinal fluid strongly suggests infection of the central nervous system",Fail,-,,
https://doi.org/10.1007/s13300-010-0010-8,.*does not cross the blood.brain barrier.*,11 It does not cross the blood-brain barrier and subsequently has a superior side-effect profile to metoclopramide with a lack of CNS effects,Fail,-,,
https://doi.org/10.1038/srep40214,.*does not cross the blood.brain barrier.*," Given that it is known that PSB1115 does not cross the blood-brain barrier38, this result suggests that A2BARs expressed on peripheral tissues (such as the large intestine) rather than those expressed in the central nervous system mediate the inhibitory effect of aminophylline on visceral hypersensitivity",Pass,CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=C(C=C3)S(=O)(=O)O,PSB1115,0
https://doi.org/10.1186/1742-2094-7-36,.*does not cross the blood.brain barrier.*," Because spontaneous cold and tactile allodynia in STZ-diabetic rats were reversed by intrathecal B1R antagonists and by peripheral administration of R-715, which does not cross the blood brain barrier, it is concluded that both spinal and peripheral B1R are involved in diabetic allodynia",Duplicate,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)C,R-715,0
https://doi.org/10.1038/s41598-017-14021-8,.*does not cross the blood.brain barrier.*, The main action of pyridostigmine is expected to be in the periphery since it does not cross the blood-brain barrier,Pass,C[N+]1=CC=CC(=C1)OC(=O)N(C)C,pyridostigmine,0
https://doi.org/10.1186/s12951-021-00879-4,.*inability to cross the blood.brain barrier.*," However, its water insolubility, poor stability and inability to cross the blood–brain barrier (BBB) limit the ability of Que to treat central nervous system (CNS) diseases [16]",Pass,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,Que,0
https://doi.org/10.1186/1477-7827-8-40,.*does not cross the blood.brain barrier.*," The apparent lack of effect of E2BSA on the secretory pattern of GnRH provides evidence that E2BSA does not have a hypothalamic effect, possibly because it does not cross the blood-brain barrier",Fail,-,,
https://doi.org/10.1203/01.pdr.0000196807.10122.5f,.*does not penetrate the blood.brain barrier.*," Indeed, treatment with the proteasome inhibitor PS519, which does not penetrate the blood-brain barrier, resulted in a marked reduction in infarction size and improvement of neuronal recovery after transient focal cerebral HI (9)",Pass,-,PS519,0
https://doi.org/10.1038/mp.2012.42,.*does not cross the blood.brain barrier.*,"72, 73 In man, the concomitant administration of codeine and quinidine, a CYP2D6 inhibitor that does not cross the blood–brain barrier and therefore only affects hepatic function, still produces the central pharmacological effects of morphine, suggesting the existence of a brain-based metabolism of codeine to morphine",Pass,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,quinidine,0
https://doi.org/10.1007/s10194-009-0170-y,.*does not cross the blood.brain barrier.*, The authors’ conclusion was that it could be a peripheral effect of the drug because “sumatriptan is a selective 5-HT (1B/1D) receptor agonist that does not cross the blood–brain barrier” [60],Duplicate,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,sumatriptan,0
https://doi.org/10.1038/ejhg.2009.160,.*unable to cross the blood.brain barrier.*," It is known that AONs are unable to cross the blood–brain barrier, and so direct injection into the spinal cord or the central nervous system is required",Fail,-,,
https://doi.org/10.1186/1742-2094-7-36,.*does not cross the blood.brain barrier.*, R-715 was also used as B1R antagonist as it does not cross the blood-brain barrier due to its peptide nature [8],Pass,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)C,R-715,0
https://doi.org/10.1186/s12967-019-2095-9,.*unable to cross the blood.brain barrier.*," Interestingly, this recent work also demonstrated that R954 is unable to cross the blood brain barrier and thus may not affect pain arising from central nervous structures",Pass,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H](CO)NC(=O)[C@](C)(CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@@H]5C[C@@H]6CCCC[C@@H]6N5C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN)NC(=O)C,R954,0
https://doi.org/10.1007/s11095-009-9939-6,.*does not cross the blood.brain barrier.*," The neurotrophin must be administered to brain via a trans-cranial route, because GDNF does not cross the blood-brain barrier (BBB) (5)",Duplicate,-,GDNF,0
https://doi.org/10.1007/s00280-009-0933-9,.*unable to penetrate the blood.brain barrier.*, The observed reduced activity for DM-PEN in IC implanted gliomas is consistent with it being a polar metabolite of PEN and either rapidly cleared or unable to penetrate the blood-brain barrier,Fail,-,,
https://doi.org/10.1038/nm1142,.*does not cross the blood.brain barrier.*," Unfortunately, ribavirin does not cross the blood-brain barrier and is expected to protect only against the visceral and not the neurological phase of Junin infection153",Pass,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,ribavirin,0
https://doi.org/10.1038/hr.2009.110,.*does not cross the blood.brain barrier.*,"6 Although it is thought that Ang II does not cross the blood–brain barrier, it has been reported that all RAS components exist in the central nervous system, suggesting that Ang II is produced and functions in the central nervous system",Duplicate,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N,Ang II,0
https://doi.org/10.1007/s11940-018-0490-9,.*does not penetrate the blood.brain barrier.*, RMP does not penetrate the blood-brain barrier (BBB) as well with concentrations in CSF only 10–20% of that reached in plasma [9],Pass,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,RMP,0
https://doi.org/10.1038/ijir.2009.19,.*does not cross the blood.brain barrier.*," It does not cross the blood–brain barrier and therefore does not have any side effects such as anxiety, agitation and insomnia common with other α-agonists",Fail,-,,
https://doi.org/10.1038/s42003-019-0520-5,.*does not cross the blood.brain barrier.*," In contrast, no reduction of [3H]-3-HK was detected in rats receiving an intravenous infusion of Ro 61-8048 (50 mg/kg), a KMO inhibitor that does not cross the blood–brain barrier4,12",Pass,COC1=C(C=C(C=C1)S(=O)(=O)NC2=NC(=CS2)C3=CC(=CC=C3)[N+](=O)[O-])OC,Ro 61-8048,0
https://doi.org/10.1038/s41467-021-24567-x,.*does not cross the blood.brain barrier.*," We reasoned that if RapaBlock does not cross the blood–brain barrier, it should produce no adverse cognitive effects when administered chronically",Pass,-,RapaBlock,0
https://doi.org/10.1038/hr.2009.5,.*does not cross the blood.brain barrier.*,"86 Although it is thought that Ang II does not cross the blood–brain barrier, it is reported that all components of RAS exist in the central nervous system, suggesting that Ang II is produced and functions in the central nervous system (Figure 3)",Duplicate,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N,Ang II,0
https://doi.org/10.1007/s00109-008-0368-5,.*inability to cross the blood.brain barrier.*," However, as a cautionary note, failure of biliverdin to exert protective effects may be due to its inability to cross the blood brain barrier (BBB)",Fail,-,,
https://doi.org/10.1203/00006450-199911000-00009,.*does not cross the blood.brain barrier.*, These findings suggest that rEpo does not cross the blood-brain barrier and that hypoxia induces increased CNS synthesis of Epo,Pass,-,rEpo,0
https://doi.org/10.1038/s41598-020-77193-w,.*does not cross the blood.brain barrier.*, The intravenous infusion of recombinant human acid alpha-glucosidase (rhGAA) rescues the muscle pathologies in PD but does not treat the CNS because rhGAA does not cross the blood–brain barrier (BBB),Pass,-,rhGAA,0
https://doi.org/10.1038/onc.2008.108,.*does not cross the blood.brain barrier.*," This suggests that either MJ does not cross the blood–brain barrier or that at the levels we administered, it was not toxic to brain cells while exhibiting selective cytotoxicity for cancer cells",Fail,-,,
https://doi.org/10.1007/s00125-006-0326-0,.*does not cross the blood.brain barrier.*," However, unlike pioglitazone, rosiglitazone does not cross the blood–brain barrier",Pass,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,rosiglitazone,0
https://doi.org/10.1038/s41598-019-55154-2,.*does not cross the blood.brain barrier.*," Following intraperitoneal (IP) administration of SBI-425, mass spectrometry analysis revealed that the SBI-425 does not cross the blood-brain barrier (BBB) in healthy mice",Pass,COC1=C(C=C(C=C1)Cl)S(=O)(=O)NC2=CN=CC(=C2)C(=O)N,SBI-425,0
https://doi.org/10.1007/s00280-018-3736-z,.*does not pass through the blood.brain barrier.*," Scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptors, is a quaternary ammonium derivative, and does not pass through the blood–brain barrier",Pass,CCCC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],Scopolamine butylbromide,0
https://doi.org/10.1186/s13195-021-00917-1,.*unable to cross the blood.brain barrier.*," However, it remains unclear how gut microbiota-produced dopamine and serotonin, which normally are unable to cross the blood–brain barrier, exert their effects on the brain by restoring deficits of human dopaminergic transmitter systems",Pass,C1=CC2=C(C=C1O)C(=CN2)CCN,serotonin,0
https://doi.org/10.1038/ejhg.2008.10,.*does not cross the blood.brain barrier.*,A major limitation of dietary cholesterol supplementation is that cholesterol does not cross the blood–brain barrier,Duplicate,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,cholesterol,0
https://doi.org/10.1038/sj.jp.7211897,.*does not cross the blood.brain barrier.*,"9 In theory, direct bilirubin does not cross the blood–brain barrier and should not contribute to the risk of kernicterus",Fail,-,,
https://doi.org/10.1203/00006450-200205000-00005,.*inability to cross the blood.brain barrier.*," The efficacies of SOD and catalase are limited by their inability to cross the blood-brain barrier and penetrate cells (21, 26)",Pass,C[C@@H]1[C@@H](C[C@@H]2[C@@H]1C[C@@]3([C@H]4CC([C@@]3([C@@]2(C4)C=O)C(=O)O)C(C)C)CO[C@H]5C[C@@H]6[C@@H]([C@H](O5)C)OCC6=C)Cl,SOD,0
https://doi.org/10.1007/s13311-016-0511-x,.*does not penetrate the blood.brain barrier.*, Multiple preclinical and clinical studies indicate that solifenacin does not penetrate the blood–brain barrier sufficiently to have a meaningful effect on cognition at doses given in this trial [23],Pass,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,solifenacin,0
https://doi.org/10.1038/sj.bmt.1705926,.*unable to cross the blood.brain barrier.*," Therapy for Hurler's syndrome includes enzyme supplementation, but the enzyme is unable to cross the blood brain barrier",Fail,-,,
https://doi.org/10.1186/1742-4690-5-11,.*unable to cross the blood.brain barrier.*," Therefore, it is possible that treatment with Akt inhibitors that are unable to cross the blood brain barrier (BBB) would result in eradication of these infected tissue macrophages",Fail,-,,
https://doi.org/10.1038/sj.bmt.1705970,.*does not cross the blood.brain barrier.*, ERT has to be administered throughout the life of the patient and does not cross the blood–brain barrier,Fail,-,,
https://doi.org/10.1038/npp.2011.77,.*does not cross the blood.brain barrier.*," Sotalol does not cross the blood–brain barrier (Dahlof, 1981), and has been shown to effectively decrease heart rate in rats to a similar extent as propranolol (Rodriguez-Romaguera et al, 2009)",Pass,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,Sotalol,0
https://doi.org/10.1038/srep28009,.*does not cross the blood.brain barrier.*," Serotonin does not cross the blood-brain barrier, thus, tryptophan can give rise to two separate pools of serotonin in the brain and in the periphery, where it is mostly found in the gastrointestinal mucosa29",Duplicate,C1=CC2=C(C=C1O)C(=CN2)CCN,Serotonin,0
https://doi.org/10.1186/2040-2392-4-37,.*does not cross the blood.brain barrier.*," Serotonin produced peripherally does not cross the blood-brain barrier of the mature brain and as such, the neurotransmitter has to be synthesized in the CNS",Duplicate,C1=CC2=C(C=C1O)C(=CN2)CCN,Serotonin,0
https://doi.org/10.1186/1748-717X-2-23,.*unable to cross the blood.brain barrier.*," By choosing boron-compounds which are unable to cross the blood-brain barrier, a largely selective irradiation of the vessel walls can be accomplished with BNCT",Fail,-,,
https://doi.org/10.1186/1744-859X-10-9,.*does not cross the blood.brain barrier.*,"Since we know that serotonin does not cross the blood-brain barrier, the mechanism described could explain the strong similarity of the low concentration of serotonin neurons and platelets in depression [16–19]",Duplicate,C1=CC2=C(C=C1O)C(=CN2)CCN,serotonin,0
https://doi.org/10.1186/ar1176,.*does not cross the blood.brain barrier.*,"Serum serotonin levels do not simply reflect CNS serotonin levels, however, since serotonin does not cross the blood–brain barrier and since CNS serotonin makes up less than 2% of total body serotonin",Duplicate,C1=CC2=C(C=C1O)C(=CN2)CCN,serotonin,0
https://doi.org/10.1038/sj.jp.7211803,.*does not cross the blood.brain barrier.*," However, total bilirubin levels are difficult to interpret in the absence of additional metabolic and nutritional information, especially since bilirubin bound to albumin does not cross the blood–brain barrier",Fail,-,,
https://doi.org/10.1007/s00247-007-0567-1,.*does not cross the blood.brain barrier.*," A lack of correlation between R2 and serum ferritin was found, possibly because serum ferritin, which does not cross the blood–brain barrier, is not a good marker of brain siderosis [106]",Pass,-,serum ferritin,0
https://doi.org/10.1038/sj.gt.3302425,.*does not cross the blood.brain barrier.*," As expected, almost no siRNA was detected in brain indicating that the complex does not cross the blood–brain barrier",Pass,-,siRNA,0
https://doi.org/10.1038/srep35885,.*inability to cross the blood.brain barrier.*,"Due to an inability to cross the blood brain barrier, SQ29548 needs to be directly delivered into the central nervous system",Pass,C1C[C@@H]2[C@H]([C@H]([C@H]1O2)C/C=C\CCCC(=O)O)CNNC(=O)NC3=CC=CC=C3,SQ29548,0
https://doi.org/10.1007/s00134-006-0452-7,.*does not cross the blood.brain barrier.*," In contrast to metoclopramide, the substance does not cross the blood-brain barrier and is therefore free of central nervous side effects",Fail,-,,
https://doi.org/10.1186/alzrt245,.*does not cross the blood.brain barrier.*," However, because squalestatin does not cross the blood-brain barrier, it does not have clinical application",Pass,CC[C@H](C)C[C@H](C)/C=C/C(=O)O[C@@H]1[C@H]([C@]2(O[C@@H]([C@]([C@@]1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCC(=C)[C@H]([C@H](C)CC3=CC=CC=C3)OC(=O)C)O,squalestatin,0
https://doi.org/10.1038/sj.npp.1301085,.*does not cross the blood.brain barrier.*," This cardiovascular response was unaffected by antalarmin, a selective CRF-R1 antagonist that readily crosses the blood–brain barrier, but was inhibited by peripheral administration of α-helical CRF9–41, which does not cross the blood–brain barrier",Fail,-,,
https://doi.org/10.1007/s10194-011-0352-2,.*does not penetrate the blood.brain barrier.*," To better explore the effect of triptans on P-CREB, two drugs with somewhat different pharmacological properties have been tested: the hydrophilic sumatriptan, which does not penetrate the blood brain barrier in normal circumstances, and the tenfold more lipophilic naratriptan [24]",Pass,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,sumatriptan,0
https://doi.org/10.1007/s00125-006-0407-0,.*unable to cross the blood.brain barrier.*, A likely explanation is that it is unable to cross the blood–brain barrier in sufficient amounts,Fail,-,,
https://doi.org/10.1038/s41467-017-02484-2,.*does not cross the blood.brain barrier.*," In order to mimic this in mice, animals were treated around day 21 post-infection with suramin (20 mg/kg), a drug that does not cross the blood brain barrier and thus only kills parasites in the periphery18",Pass,CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C,suramin,0
https://doi.org/10.1007/s11060-006-9308-9,.*inability to cross the blood.brain barrier.*, He noted that earlier studies of taxol in vitro showed that it destroyed targeted cells but in vivo studies showed it to have little to no efficacy owing to its inability to cross the blood–brain barrier [17–23],Pass,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,taxol,0
https://doi.org/10.1186/1742-2094-4-5,.*does not cross the blood.brain barrier.*," Although squalestatin is the more specific research tool, it does not cross the blood-brain barrier, which limits its therapeutic value",Duplicate,CC[C@H](C)C[C@H](C)/C=C/C(=O)O[C@@H]1[C@H]([C@]2(O[C@@H]([C@]([C@@]1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCC(=C)[C@H]([C@H](C)CC3=CC=CC=C3)OC(=O)C)O,squalestatin,0
https://doi.org/10.1038/oncsis.2017.33,.*unable to cross the blood.brain barrier.*,"In its current format, THZ1 was unable to cross the blood–brain barrier and provide effective antitumor therapy",Pass,CN(C)C/C=C/C(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl,THZ1,0
https://doi.org/10.1007/s10194-009-0170-y,.*unable to cross the blood.brain barrier.*,"Sumatriptan, a relatively hydrophilic triptan, based on several animal studies has been regarded to be unable to cross the blood–brain barrier (BBB)",Duplicate,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,Sumatriptan,0
https://doi.org/10.1186/ar1905,.*unable to cross the blood.brain barrier.*, New p38 MAPK inhibitors that are unable to cross the blood-brain barrier are now in clinical trials in rheumatoid arthritis and will delineate precisely the role of p38 MAPK in Th1-driven chronic inflammatory diseases,Fail,-,,
https://doi.org/10.1038/sj.gt.3302665,.*inability to cross the blood.brain barrier.*," When delivered through oral or systemic routes, these peptides are not feasible due to a short half-life in vivo and inability to cross the blood–brain barrier, and often cause harmful adverse effects",Fail,-,,
https://doi.org/10.1186/1471-2202-7-3,.*does not penetrate the blood.brain barrier.*,"Thus, we conclude that, most likely, CBX does not penetrate the blood brain barrier and therefore recommend careful consideration in the manner of administration, when a central effect is desired",Fail,-,,
https://doi.org/10.1007/s00401-019-01998-x,.*does not cross the blood.brain barrier.*,"Although torkinib restored protein homeostasis in spinal neuronal cultures, torkinib does not cross the blood–brain barrier, thus limiting its use as an oral ALS therapeutic (although intrathecal delivery might be possible)",Pass,CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(N3)C=CC(=C4)O)N,torkinib,0
https://doi.org/10.1038/sj.npp.1300811,.*does not penetrate the blood.brain barrier.*," One non-human primate study found that nalmefene suppressed basal prolactin, whereas its quaternary ammonium form, which does not penetrate the blood–brain barrier, had no effect on prolactin (Simpkins et al, 1991)",Fail,-,,
https://doi.org/10.1007/s13311-020-00897-4,.*does not cross the blood.brain barrier.*," Trospium, yet another newer anticholinergic drug, does not cross the blood–brain barrier but has not been specifically tested in PD patients",Pass,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O,Trospium,0
https://doi.org/10.1203/01.PDR.0000157679.67227.11,.*unable to cross the blood.brain barrier.*," 10 min before capsaicin (23,25,26); and 4) bicuculline methiodide, inhibitor of peripheral GABAA receptors unable to cross the blood-brain barrier, 3 mg/kg i",Fail,-,,
https://doi.org/10.1186/s13028-018-0380-x,.*does not cross the blood.brain barrier.*," Because vatinoxan does not cross the blood brain barrier in significant amounts, it has only minor effect on sedation induced by α-2 adrenoceptor agonists",Pass,CS(=O)(=O)NCCN1C(=O)NC[C@]12CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45,vatinoxan,0
https://doi.org/10.1186/1477-7827-3-10,.*does not cross the blood.brain barrier.*," It is important to note that this compound does not cross the blood-brain barrier [14, 15] and hence, the levels of gonadotropins and testosterone remain unchanged during this treatment [16]",Fail,-,,
https://doi.org/10.1186/s40360-020-00465-8,.*does not cross the blood.brain barrier.*," However, TMA+ does not cross the blood-brain barrier [20]",Pass,-,TMA+,0
https://doi.org/10.1007/s00508-021-01948-2,.*does not cross the blood.brain barrier.*," This might be due to the fact that tocilizumab does not cross the blood-brain barrier [16]; however, IL‑6 is likely involved in the pathogenesis of CAR T-related neurotoxicity and levels of IL‑6 have shown to rise transiently following tocilizumab administration, which might lead to an aggravation of neurologic symptoms [16]",Pass,-,tocilizumab,0
https://doi.org/10.1186/s40425-018-0343-9,.*does not cross the blood.brain barrier.*," Monoclonal antibodies that target IL-6 directly, thereby eliminating it from the circulation, might be advantageous in patients with severe CRS and concurrent neurotoxicity, since tocilizumab does not cross the blood brain barrier and therefore fails to inhibit IL-6 signaling in the CNS",Duplicate,-,tocilizumab,0
https://doi.org/10.1097/01.GIM.0000154299.22120.6A,.*inability to cross the blood.brain barrier.*,"7,8 However, a limitation of intravenous ERT is its inability to cross the blood brain barrier9; hence, it is not predicted to help the central nervous system directly",Fail,-,,
https://doi.org/10.1038/s41467-019-09494-2,.*does not cross the blood.brain barrier.*," However, verapamil does not cross the blood–brain barrier (BBB) and is therefore not suitable to this end",Pass,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,verapamil,0
https://doi.org/10.1186/2046-0481-57-10-593,.*does not penetrate the blood.brain barrier.*," Intrathecal (intracisternal) antitoxin administration has been recommended in severely affected animals, as the antitoxin does not penetrate the blood-brain barrier",Fail,-,,
https://doi.org/10.1007/s12031-010-9425-y,.*does not cross the blood.brain barrier.*," In contrast to previously reported MCH1R antagonists, TPI13161-17 does not cross the blood–brain barrier and is thus administered intracerebroventricularly (i",Pass,-,TPI13161-17,0
https://doi.org/10.1038/sj.bjc.6601970,.*does not cross the blood.brain barrier.*,"Firstly, longer survival of patients receiving trastuzumab (which does not cross the blood brain barrier) may allow the development of symptomatic BM, which otherwise would have remained clinically silent",Duplicate,-,trastuzumab,0
https://doi.org/10.1007/s10549-017-4225-5,.*does not cross the blood.brain barrier.*," We show Trastuzumab treatment resulted in a reduction in metastasis to all sites, except the brain which is explained by the fact that Trastuzumab does not cross the blood/brain barrier [25, 26]",Pass,-,Trastuzumab,0
https://doi.org/10.1186/s40425-015-0084-y,.*does not cross the blood.brain barrier.*," Given that IV trastuzumab does not cross the blood–brain barrier or blood CSF barrier, IT trastuzumab offers a direct approach to the leptomeninges",Duplicate,-,trastuzumab,0
https://doi.org/10.1007/s10549-012-2328-6,.*does not cross the blood.brain barrier.*," Because trastuzumab does not cross the blood–brain barrier (BBB), the CNS serves as a sanctuary for metastatic disease in the setting of sustained extracranial control and improved survival",Duplicate,-,trastuzumab,0
https://doi.org/10.1007/s00125-003-1284-4,.*unable to cross the blood.brain barrier.*, To avoid this hypothalamic interference by specific 11β-HSD1 inhibitors such drugs should be unable to cross the blood brain barrier,Fail,-,,
https://doi.org/10.1186/ar1014,.*unable to cross the blood.brain barrier.*, Opioid peptides unable to cross the blood-brain barrier are the natural ligands for opioid receptors,Fail,-,,
https://doi.org/10.1038/sj.npp.1300215,.*does not cross the blood.brain barrier.*," Exogenous CRF does not cross the blood–brain barrier (Martins et al, 1996) but can affect periventricular structures, particularly the hypothalamus",Fail,-,,
https://doi.org/10.1007/s13691-012-0054-x,.*inability to cross the blood.brain barrier.*," High effectiveness of trastuzumab cannot be expected for brain metastases because of its large molecular weight and inability to cross the blood–brain barrier [9, 10]",Duplicate,-,trastuzumab,0
https://doi.org/10.1186/cc1835,.*inability to cross the blood.brain barrier.*,"Catecholamines normally have no effect on cerebral blood flow, which is at least partly due to their inability to cross the blood–brain barrier",Fail,-,,
https://doi.org/10.4076/1752-1947-3-9110,.*does not cross the blood.brain barrier.*," Trastuzumab does not cross the blood–brain barrier [17], suggesting that targeting Her2/neu positive systemic disease may alter the natural history of bladder carcinoma metastasis predisposing to the onset and progression of central nervous system (CNS) disease",Duplicate,-,Trastuzumab,0
https://doi.org/10.1186/bcr1870,.*does not cross the blood.brain barrier.*," Although trastuzumab does not cross the blood-brain barrier and has no direct activity on brain metastases, several studies have shown a survival benefit with trastuzumab in HER2-positive patients with BM, who had a significantly longer survival time compared with HER2-negative patients [20, 21]",Duplicate,-,trastuzumab,0
https://doi.org/10.1038/sj.bjc.6601970,.*does not cross the blood.brain barrier.*,"Firstly, trastuzumab therapy controls systemic disease and prolongs survival (Slamon et al, 2001), but does not cross the blood–brain barrier (BBB), making the CNS a ‘sanctuary site’, allowing the development of symptomatic BM which otherwise would have remained clinically silent prior to death",Duplicate,-,trastuzumab,0
https://doi.org/10.1038/sj.gt.3301682,.*inability to cross the blood.brain barrier.*,234 Administration of GDNF protein in the central nervous system is limited by its short activity and inability to cross the blood–brain barrier,Fail,-,,
https://doi.org/10.1186/1471-2210-2-6,.*does not cross the blood.brain barrier.*," The contribution of N-desmethylclozapine to clozapine's central effects has been questioned recently, since the levels of N-desmethylclozapine in the brain were much lower than those of clozapine [30] suggesting that N-desmethylclozapine does not cross the blood-brain barrier as readily as clozapine",Fail,-,,
https://doi.org/10.1016/S0893-133X(01)00297-4,.*does not cross the blood.brain barrier.*," John's wort, was not detected in the cerebrospinal fluid of nonhuman primates after intravenous administration of extremely large doses (> 2 mg/kg), suggesting that the compound does not cross the blood-brain barrier to any appreciable extent (Fox et al",Fail,-,,
https://doi.org/10.1038/s41598-018-33215-2,.*does not cross the blood.brain barrier.*," However, ziconotide does not cross the blood brain barrier and has to be delivered to the central nervous system via intrathecal injection, an invasive delivery method that limits its use35,36",Pass,C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N3)CO)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN,ziconotide,0
https://doi.org/10.1038/sj.gt.3301219,.*unable to cross the blood.brain barrier.*," Large molecules delivered to peripheral sites in an animal rarely reach the central nervous system as they are unable to cross the blood–brain barrier, unless they are part of an entity encoding specific functions to overcome this barrier, for example herpes simplex virus",Fail,-,,
https://doi.org/10.1038/s12276-018-0166-2,.*does not cross the blood.brain barrier.*," Zoledronate enhances the anti-tumor effect of temozolomide in glioblastoma cell lines54; however, it does not cross the blood–brain barrier (BBB)55",Pass,C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O,Zoledronate,0
https://doi.org/10.1038/sj.gt.3301119,.*unable to cross the blood.brain barrier.*,"138 Delivery of ODNs can be problematic, however, since they are unable to cross the blood–brain barrier",Fail,-,,
https://doi.org/10.1007/s40262-017-0546-0,.*does not penetrate the blood.brain barrier.*," After a single IV infusion of vedolizumab 450 mg in healthy volunteers, vedolizumab was not detected in the cerebrospinal fluid, suggesting that vedolizumab does not penetrate the blood–brain barrier [15]",Pass,-,vedolizumab,0
https://doi.org/10.1203/PDR.0b013e318180ebe6,.*does not cross the blood.brain barrier.*," Interestingly, VEGF has been ineffective or detrimental when administered via the systemic route (11,24) because it causes an immune response and does not cross the blood-brain barrier (BBB) (25)",Pass,-,VEGF,0
https://doi.org/10.1203/00006450-199911000-00009,.*does not cross the blood.brain barrier.*,"Thus, the present study was performed to test the following two hypotheses:1) Epo concentrations in CSF are higher among neonates with brain injury (asphyxia, IVH, or meningitis) than in those without such injury;2) in neonates who have no evidence of brain injury, Epo does not cross the blood-brain barrier, but, in neonates with asphyxia, IVH, or meningitis, Epo does",Fail,-,,
https://doi.org/10.1038/sj.npp.1301085,.*does not cross the blood.brain barrier.*," This cardiovascular response was unaffected by antalarmin, a selective CRF-R1 antagonist that readily crosses the blood–brain barrier, but was inhibited by peripheral administration of α-helical CRF9–41, which does not cross the blood–brain barrier",Pass,CCCCN(CC)C1=NC(=NC2=C1C(=C(N2C3=C(C=C(C=C3C)C)C)C)C)C,antalarmin,1
https://doi.org/10.1203/00006450-199903000-00008,.*inability to pass through the blood.brain barrier.*,"The lack of significant protective effect of U74389F in our model of excitotoxic brain lesions could be due to its inability to pass through the blood-brain barrier, to achieve sufficient concentration near the site of free radical generation, or to compete efficiently with endogenous targets of free radical attacks (membranes and DNA)",Fail,-,,
https://doi.org/10.1186/s13023-021-02063-1,.*does not cross the blood.brain barrier.*," Although vestronidase alfa does not cross the blood brain barrier, it was interesting to note that most of the treated patients had a favorable neurocognitive evolution",Pass,-,vestronidase alfa,0
https://doi.org/10.1203/00006450-200106000-00016,.*does not cross the blood.brain barrier.*," Unlike BN 52021 and BN 50730, which are both lipophilic and presumed to cross the blood-brain barrier, WEB 2170 is water soluble and does not cross the blood-brain barrier (43)",Pass,-,WEB 2170,0
https://doi.org/10.1007/s00125-006-0326-0,.*does not cross the blood.brain barrier.*," However, unlike pioglitazone, rosiglitazone does not cross the blood–brain barrier",Pass,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,pioglitazone,1
https://doi.org/10.1007/s11682-010-9098-8,.*does not pass through the blood.brain barrier.*," Nadolol does not pass through the blood-brain barrier while propranolol does, and therefore nadolol has the same peripheral effects without any of the central effects of propranolol",Pass,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,propranolol,1
